



The ozone paradox: Ozone is a strong oxidant as well as a medical drug

This is a pre print version of the following article:

Original:

Bocci, V., Borrelli, E., Travagli, V., Zanardi, I. (2009). The ozone paradox: Ozone is a strong oxidant as well as a medical drug. *MEDICINAL RESEARCH REVIEWS*, 29(4), 646-682 [10.1002/med.20150].

Availability:

This version is available <http://hdl.handle.net/11365/8222> since 2016-11-19T17:31:17Z

Publisher:

John Wiley & Sons Incorporated:Customer Service, 111 River Street:Hoboken, NJ 07030:(800)225-5945,

Published:

DOI:10.1002/med.20150

Terms of use:

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)



The Ozone Paradox: Ozone Is a Strong Oxidant as Well as a Medical Drug

Q1

Velio Bocci,¹ Emma Borrelli,² Valter Travagli³ and Iacopo Zanardi³

¹Department of Physiology, University of Siena, Siena, Italy

²Department of Surgery and Bioengineering, University of Siena, Siena, Italy

³Department of Pharmaceutical Chemistry and Technology, University of Siena, Siena, Italy

Published online xx May 2008 in Wiley InterScience (www.interscience.wiley.com).

DOI 10.1002/med.0000

Abstract: After five decades characterized by empiricism and several pitfalls, some of the basic mechanisms of action of ozone in pulmonary toxicology and in medicine have been clarified. The present knowledge allows to understand the prolonged inhalation of ozone can be very deleterious first for the lungs and successively for the whole organism. On the other hand, a small ozone dose well calibrated against the potent antioxidant capacity of blood can trigger several useful biochemical mechanisms and reactivate the antioxidant system. In detail, firstly *ex vivo* and second during the infusion of ozonated blood into the donor, the ozone therapy approach involves blood cells and the endothelium, which by transferring the ozone messengers to billions of cells will generate a therapeutic effect. Thus, in spite of a common prejudice, single ozone doses can be therapeutically used in selected human diseases without any toxicity or side effects. Moreover, the versatility and amplitude of beneficial effect of ozone applications have become evident in orthopedics, cutaneous, and mucosal infections as well as in dentistry.

© 2008 Wiley Periodicals, Inc. *Med Res Rev*, 00, No. 0, 1–37. 2008

Key words: oxidative stress; antioxidants; oxidative preconditioning; ozone; ozonated autohemotherapy

Abbreviations

ALDH	aldehyde dehydrogenase
ARMD	age-related macular degeneration
ASF	airway surface fluid
ATP	adenosine triphosphate
BMC	blood mononuclear cells
CAT	catalase
CCl ₄	carbon tetrachloride
CGMP	cyclic guanosine monophosphate

Correspondence to: Velio Bocci, Department of Physiology, University of Siena, Via Moro 2, 53100 Siena, Italy, E-mail: bocci@unisi.it

1	CO	carbon monoxide
	COPD	chronic obstructive pulmonary disease
3	COX-2	cyclooxygenase-2
	CHF	chronic heart failure
5	CNS	central nervous system
	DPG	2,3-diphosphoglycerate
7	ELF	epithelial lining fluid
	G6PHD	glucose-6-phosphate dehydrogenase
9	GSH	glutathione
	GSH-Rd	glutathione reductase
11	GSSG	oxidized glutathione
	GST	glutathione-S-transferases
13	GSPase	glutathione peroxidase
	HAART	highly active anti-retroviral therapy
15	HClO	hypochloric acid
	HCV	hepatitis C virus
17	HIV	human immunodeficiency virus
	4-HNE	4-hydroxynonenal
19	HO-1	heme oxygenase-1
	HOT	hyperbaric oxygen therapy
21	H ₂ O ₂	hydrogen peroxide
	HSP	heat stress proteins
23	HSV	herpes simplex viruses
	HUVEC	human vascular endothelial cells
25	IL-1	interleukin-1
	IL-8	interleukin-8
27	IFN γ	interferon gamma
	LDH	lactate dehydrogenase
29	L-NAME	<i>n</i> -omega-nitro-L-arginine methyl ester
	LOP	lipid oxidation products
31	MDA	malondialdehyde
	MA	mercapturic acid
33	NADPH	nicotinamide adenine dinucleotide phosphate
	NF- κ B	nuclear factor- κ B
35	NO	nitric oxide
	N ₂ O	nitric dioxide
37	O ₂ ⁻	anion superoxide
	\cdot OH	hydroxyl radical
39	O ₃ -AHT	ozonated autohemotherapy
	PDGF	platelet-derived growth factor
41	POAD	peripheral obstructive arterial disease
	ppm	parts per million
43	PUFA	polyunsaturated fatty acids
	RBC	red blood cells
45	ROS	reactive oxygen species
	PRE	pigmented retinal epithelium
47	SOD	superoxide dismutase
	TAS	total antioxidant status
49	TBARS	thiobarbituric acid reactive substances
	TGF β 1	transforming growth factor β 1

1	TNF α	tumor necrosis factor alpha
	Trx	thioredoxin
3	UV	ultraviolet radiation
	VEGF	vascular endothelial growth factor

1. INTRODUCTION

A. A Brief Historical Review

Christian Friedrich Schönbein, in 1839, noticed the emergence of a pungent gas with an “electric smell.” According to the Greek language, he called it “ozone” and presented a lecture entitled “On the smell at the positive electrode during electrolysis of water” at the Basel Natural Science Society.^{1,2} In nature ozone is continuously produced in the stratosphere (at 25–30 km from the Earth surface) by UV radiation (<183 nm) by splitting an atmospheric oxygen molecules into two highly reactive oxygen atoms, in agreement with the Chapman theory. By an endothermic reaction, each of these atoms combines to intact oxygen to form the triatomic ozone.

It is also produced during the electric discharge of lightning, which catalyzes the formation of ozone from atmospheric oxygen. Ozone has a molecular weight of 48 and it is a bluish gas with a pungent odor and a solubility in water, about ten-fold higher than oxygen (49 mL in 100 mL, 0.02 M, at 0°C), even though an ample variability is present in the literature.³ While it rapidly dissolves in pure water and obeys Henry’s law, in biological water ozone instantly reacts with inorganic and organic molecules dissolved in water generating a variety of free radicals. Ozone as a gas spontaneously decomposes with a half-life of 40 min, at 20°C. This means that ozone is a metastable gas with a temperature-dependent half-life, but it can be stored in liquid form at –183°C with a specific weight of 1.571 g/mL. Methods for generating ozone are based on UV radiation, corona discharge, and an electrochemical process. Industrial ozone is produced from air but medical ozone must be generated ex tempore only by using medical oxygen because otherwise the simultaneous generation of nitric dioxide (NO₂) will be very toxic.⁴ The most recent medical ozone generator can control the electric voltage from 5 kV up to about 14 kV, the space between the electrodes able to modulate a gradual increase in ozone concentration and the flow of pure oxygen usually regulated between 1 and 10 L/min. The final ozone concentration is inversely proportional to the oxygen flow, hence, per unit time, the higher the oxygen flow, the lower the ozone concentration. In the final oxygen–ozone mixture, the maximum ozone concentration can be only 5%.

2. BEHAVIOR OF OZONE

A. Ozone as an Oxidant

Ozone has a cyclical structure assessed by the absorption at 253.7 nm with a distance among oxygen atoms of 1.26 Å and exists in several mesomeric states in dynamic equilibrium⁵ (Fig. 1). Among oxidant agents, it is the third strongest ($E^\circ = +2.076$ V), after fluorine and persulphate. Molecular oxygen, by containing two unpaired electrons, is a diradical but it has not the reactivity of ozone and, by a stepwise reduction with four electrons, forms water. On the other hand, ozone having a paired number of electrons in the external orbit is not a radical molecule, but it is far more reactive than oxygen and generates some of the radical




Figure 1. Structure and mesomeric states of ozone.

oxygen species (ROS) produced by oxygen during mitochondrial respiration. Phagocytes reacting with pathogens⁶⁻⁸ produce anion superoxide (O_2^-), H_2O_2 , and hypochlorous acid (HClO) catalyzed by myeloperoxidase. Wentworth et al.^{9,10} have postulated that in atherosclerotic patients human endothelium cells may produce ozone, but their finding remains doubtful.¹¹ Moreover, H_2O_2 is produced by almost all cells by the nicotinamide adenine dinucleotide phosphate (NADPH)-oxydase isoenzymes, indicating the relevance of ROS in the normal organism. Interestingly, ozone, in the presence of inorganic and/or organic compounds immediately reacts and generates a great variety of oxidized molecules, disappearing in a matter of seconds.¹²

19 **B. Ozone as UV screen**

In the stratospheric layer, ozone has an average concentration of 10 parts per million (ppm) and it has the important role to absorb most of the UV radiations, particularly bands B (from 280 to 320 nm) and C (from 100 to 280 nm), which are mutagenic and can enhance skin carcinogenesis.¹³ Unfortunately, during the last decades, short-sighted human activities, by releasing chlorofluorocarbons in the atmosphere, have led to a decreased ozone concentration, particularly in the Antarctic, which will take several decades to be restored.

27 **C. Ozone as an Air Pollutant**

On the other hand, the tropospheric amount of ozone ought to be about $1 \mu\text{g}/\text{m}^3$ (0.001 ppm), ten times lower than our odor perception threshold for ozone about $20 \mu\text{g}/\text{m}^3$ (0.02 ppm). However during the last decades, in large cities, ozone levels in summer time can increase up to dangerous levels ranging from 200 to $900 \mu\text{g}/\text{m}^3$. Moreover, additional anthropogenic emissions of NO, NO_2 , methane, CO, sulphuric compound, and fine particulates have enhanced the toxicity not only for the respiratory tract but also for the eyes and the skin.

The US Clean Air Act has set an ozone level of $120 \mu\text{g}/\text{m}^3$ as an 8 hr mean concentration to protect the health of workers.¹⁴ Evaluation of recent studies¹⁵⁻¹⁸ allows establishing an average environmental ozone concentration of $90 \pm 10 \mu\text{g}/\text{m}^3$. However, ozone concentration in urban air can exceed 0.8 ppm in high pollution conditions.^{19,20} For 8 hr at rest (a tidal volume of about 10 L/min and a retention of inspired ozone of no less than 80%), the ozone dose amounts to 0.70–0.77 mg daily. This is likely the minimal ozone intake because physical activity increases the volume of inhaled air, and, at peak time, the ozone levels can easily augment to $500\text{--}900 \mu\text{g}/\text{m}^3$, reducing pulmonary functions and markedly enhancing the risk of cardiovascular deaths.^{15,17,18}

Ozone levels of $500 \mu\text{g}/\text{m}^3$ may not seem too high but one must consider that any single air inhalation implies an ozone dose that immediately reacts with the airway surface fluid and immediately at the epithelial lining fluid (ELF) generates the ROS and lipid oxidation products (LOP) minimally quenched by the scarce antioxidant present in a liquid film of about $0.1 \mu\text{m}$.²¹ As a consequence, the whole respiratory tract against the continuous inhalation of ozone-contaminated air opposes only the ELF's volume of about 20–40 mL,²² which is negligible when compared to a plasma volume of about 2700 mL. Thus, throughout the day we must consider, neither simply the ozone concentration nor a single respiratory act, but the ozone cumulative

1 dose that can easily sum up to 1–2 g ozone in 5 months. While ozone vanishes within the ELF,²³
2 the generated ROS, LOP, and nitrating species^{24–28} damage the epithelial lining. The phos-
3 phorylation of a protein kinase, by activating the nuclear factor- κ B (NF- κ B), allows the
4 synthesis and release of a number of cytokines such as TNF α , IL-1, IL-8, IFN γ , and TGF β 1.
5 Moreover, this situation starts a vicious circle because the increased inflow of neutrophils and
6 activated macrophages into the alveolar space worsens and perpetuates the production of more
7 ROS including HClO,^{8,26} tachykinins, proteases, alkenals, and F₂-isoprostanes^{25,29} able to self-
8 maintain a chronic inflammation. ROS have a very brief half-life and damage mostly the
9 pulmonary microenvironment while alkenals and proinflammatory cytokines are absorbed by the
10 human large expanse (about 70 m²) of the bronchial–alveolar space. Recent studies^{25,30,31} have
11 detected 4-hydroxynonenal (4-HNE), isoprostanes, H₂O₂, and malondialdehyde (MDA) in the
12 bronchoalveolar lavage fluid. The interesting study by Last et al.³² has clearly shown that mice
13 exposed to 1 ppm for 8 hr during three consecutive nights lose about 14% of their original body
14 weight, decrease their food consumption by 42%, and enter into a cachectic state. Another
15 important aspect of the pulmonary ozone toxicity is its reverberation on the whole organism,
16 especially on the vascular system, heart, liver, brain, and kidneys. The pharmaco-toxicological
17 behavior of both LOP compounds, ceramide signaling, and proinflammatory cytokines is
18 characterized by a continuous absorption from the pulmonary area into the blood and, even
19 though the half-life of these compounds is brief,^{28,33–37} the constant endogenous synthesis
20 insures a constant toxicity explaining the increased morbidity and mortality of population
21 inhaling polluted air for several months of the year.

23 ***D. Ozone as a Biological Cytotoxic Agent***

25 Either normal or neoplastic cells in culture are very sensitive to a constant exposure of ozone
26 even if the gas has a very low concentration.^{38–40} This observation is correct but it has led to the
27 misleading conclusion that ozone is always cytotoxic. Indeed, we know too well that cells culture
28 studies are mostly performed with air–CO₂ at pH 7.3 but with a p O₂ of 160 mmHg, i.e. more
29 than double of cells in vivo. Even more important is the fact that culture media have a sig-
30 nificantly lower level of antioxidants than plasma, particularly of albumin.^{41–45} Indeed, the
31 usual fetal calf serum is added at a 5–10% concentration that is equivalent to hardly 50% of the
32 albumin present in the extracellular fluid. Among antioxidants, albumin with its available –SH
33 reducing group is one of the most protective compounds.⁴⁶ Moreover, antioxidant components
34 are not dynamically replenished in vitro while cells remain exposed to a constant ozone con-
35 centration. Obviously ozone dissolves in the fluid every second, exhausts the scarce antioxidants,
36 and generates toxic compounds that cannot undergo either dilution with extracellular fluid or
37 excretion. This unfavorable situation has been demonstrated when thiobarbituric acid reactive
38 substances (TBARS), incubated in vitro at 37°C and pH 7.3 in human ozonated plasma remain
39 at a constant level for 9 hr.⁴⁷ On the other hand TBARS present in ozonated blood declined
40 very rapidly with a half-life of 4.2 ± 1.7 min^{48,49} after intravenous infusion in patients with age-
41 related macular degeneration (ARMD) demonstrating the relevance of critical pharmacological
42 properties to be extensively discussed in Section 4A. Moreover, the damaging effect of ozone on
43 saline washed erythrocytes, totally deprived of the plasma protection, has noticeably con-
44 tributed to consider ozone as a deleterious gas.

47 **3. MAY OZONE BE USED AS A MEDICAL DRUG?**

49 At first sight, the strong oxidizing properties of ozone discard the possibility that this gas may
50 display some therapeutic effects. However, even today some ozonetherapists advance the

1 whimsical idea that ozone, by decomposing in the blood, gifts the body its intrinsic energy
 2 accumulated during its synthesis, as shown

3



5 On the 19th century, ozone had been already identified as a potent bactericidal gas and it was
 6 used during World War I for treating German soldiers affected by gaseous gangrene due to
 7 *Clostridium* anaerobic infections. In two pioneering studies, Stoker^{50,51} reported the first 21
 8 medical cases successfully treated with ozone at the German Alexandria Military Hospital. It
 9 remains uncertain how a Swiss dentist, E.A. Fisher (1899–1966)⁵² had the first idea to
 10 use ozone as either a gas or ozonated water in his practice. By a twist of fate, a surgeon,
 11 Dr. E. Payr (1871–1946) had to be treated for a gangrenous pulpitis and remained astonished
 12 by the result achieved with local ozone treatment. He enthusiastically extended its application
 13 to general surgery and at the 59th Congress of the German Surgical Society (Berlin, 1935)
 14 reported “which other disinfectant would be tolerated better than ozone? The positive results
 15 in 75% of patients, the simplicity, the hygienic conditions and the safety of the method are
 16 some of the many advantages.”⁵³ In 1936, a French physician, Dr. P. Aubourg successfully
 17 treated chronic colitis and rectal fistulae by the direct insufflation of oxygen–ozone mixture
 18 into the rectum. It seems that Dr. Payr was the first to inject a small volume of the O₂–O₃ gas
 19 mixture directly into the human cubital vein, giving rise to a procedure that in the 90s,
 20 adopted by charlatans, became so dangerous to be prohibited. After the invention of the first
 21 medical ozone generator by the physicist Joachim Hansler (1908–1981), the physician Hans
 22 Wolff (1927–1980) deserves the credit for having developed the ozonated autohemotherapy
 23 (O₃-AHT) by insufflating *ex vivo* the gas into the blood contained in a dispensable ozone-
 24 resistant glass bottle. For almost three decades ozone therapy was used in Germany but the
 25 lack of scientific and clinical studies arose scepticism and prejudice still common today.
 26 Lacking the knowledge of the complexity of biological mechanisms, a distinguished chemist
 27 wrote that “ozone is toxic, no matter how you deal with it and should not be used in
 28 medicine” (personal communication to V.B.).⁵⁴ This negative concept may only be changed
 29 by valid scientific and clinical data. It is worthwhile to mention what Timbrell⁵⁵ wrote in his
 30 book “*The poison paradox; chemicals as friends and foes.*” The essential facts are that first it is
 31 the dose that makes a chemical toxic, and second and more important, toxicity results from
 32 the interaction between chemical and biological defenses. Indeed the subtlety and complexity
 33 of biological systems may defy the concept that ozone is always toxic. Interestingly,
 34 Paracelsus (1495–1541) did not know biochemistry but guessed that “all things are poison
 35 and nothing is without poison, only the dose permits something not to be poisonous.”⁵⁶

37

38 **4. BIOLOGICAL MECHANISMS ELICITED BY OZONE IN HUMAN BLOOD**

39


40 As it was mentioned, ozone as a gas equilibrates in 5 min in pure water and, in a closed glass
 41 bottles, its concentration (about 25% of the ozone concentration in the gas mixture) remains
 42 fairly stable for many hours. However, in a physiological environment, it immediately reacts
 43 with antioxidants, polyunsaturated fatty acids (PUFA), proteins, carbohydrates and, if in
 44 excess, with DNA and RNA.^{57,58} Thus, ozone leads to the formation of ROS, LOP, and a
 45 variable percentage of oxidized antioxidants.^{59,60}

47

A. Reactions with Plasma Components

48 Blood is an ideal tissue because it is composed of about 55% plasma and cells, especially
 49 erythrocytes, able to cooperate for taming the oxidant properties of ozone. The plasma has a

1 wealth of hydrophilic reductants, such as ascorbic acid ($\sim 50 \mu\text{M}$), uric acid ($\sim 400 \mu\text{M}$), and a
 3 little amount of reduced glutathione (GSH). These compounds have been measured before
 5 and after ozonation.^{61–63} Plasma contains albumin ($\sim 45 \text{ mg/mL}$) that by virtue of a wealth of
 7 $-\text{SH}$ groups, is one of the most important antioxidants also because the plasma pool contains
 9 about 112 g of albumin.⁴⁶ Moreover, the presence of proteins such as transferrin and cer-
 uloplasmin quenches oxidizing reactions by chelating transition metals (mainly Fe^{2+} and
 Cu^+). Presence of traces of these metals must be avoided because either in the presence of
 hydrogen peroxide, via the Fenton's reaction, or in the presence of anion superoxide (O_2^-) via
 the Haber–Weiss reaction, they will catalyze the formation of the most reactive hydroxyl
 radical $\cdot\text{OH}$.



15 Although $\cdot\text{OH}$ has a half-life of 1×10^{-9} sec, it reacts with any other molecule and
 produces another radical. Blood cells contain not only the bulk of GSH (1–5 mM) but also
 17 thioredoxin and several lipophilic compounds such as α -tocopherol, retinol, lycopene,
 ubiquinol, and α -lipoic acid, which are able to cooperatively reduce oxidized compounds,
 19 thus restoring the initial antioxidant status. Moreover, blood cells contain a variety of en-
 zymes (SOD, catalase, GSPase, GSH-redox system), which cooperate either simultaneously
 21 or in a sequential way to restore the redox system. The work performed during the last 18
 years in our lab has clarified the most important compounds generated ex vivo during the
 23 initial reaction of ozone with some plasma components and how these compounds activate
 some biochemical pathways in cells revealed by therapeutic effects after the transfusion of
 25 ozonated blood in the donor.

The biochemical effects displayed by ozone when it comes in contact with blood com-
 27 ponents will be briefly reviewed.^{47,63} After having performed thousands of treatments, the
 standard procedure is to add 200 mL of a gas mixture composed of medical oxygen ($>95\%$)
 29 with ozone ($<5\%$) to 180 mL of blood after the previous addition of 20 mL of 3.8% sodium
 citrate at room temperature. The blood–gas volumes are gently mixed in a sterile glass bottle
 31 by rotation, avoiding gas bubbling. Within 5 min, about 1.5 mL of O_2 and 2.4 mL of O_3
 dissolve in the blood water but their fate is quite different. Oxygen physically diffuses into
 33 erythrocytes and fully saturates hemoglobin (Hb_4O_8) but in spite of the $p\text{O}_2$ as high as
 450 mmHg, the therapeutic value of oxygenation is irrelevant because the successive infusion
 35 of oxygenated–ozonated blood (about 15 mL/min) hardly modify the $p\text{O}_2$ ($\sim 40 \text{ mmHg}$) of
 about 5 L/min of the simultaneous venous blood inflow to the heart. On the contrary, ozone
 37 dissolves more readily in plasma water than oxygen, and instantaneously reacts with
 hydrosoluble antioxidants and with readily available PUFA bound to albumin.

39 Several years ago, by using a reliable ozone generator able to deliver precise
 ozone concentrations, the first aim was to define if indeed ozone was always deleterious
 41 or if a range of ozone therapeutic concentrations could be determined. The range was
 determined between $10 \mu\text{g/mL}$ gas ($0.21 \mu\text{mol/mL}$) and $80 \mu\text{g/mL}$ gas ($1.68 \mu\text{mol/mL}$)
 43 per mL of anticoagulated blood, corresponding to total ozone doses comprises between
 1 and 8 mg for 100 mL blood, respectively. It was crucial to precisely calibrate the ozone
 45 dose (gas volume \times ozone concentration) against the individual variable antioxidant
 capacity of the patient's blood, thereby on one hand avoiding ozone toxicity and, on
 47 the other hand, allowing the activation of several biochemical pathways on blood cells.
 It was proven that during the slow mixing of the blood with the gas phase, all the ozone is
 49 consumed in less than 5 min. Several studies^{47,51,59,63–65} have clarified that some albumin
 and uric acid behave as sacrificial molecules whereas several antioxidants after oxidation

1 are rapidly reduced by an efficient recycling system.^{66,67} Some ozone reacts with PUFA as follows

3

5

7

9



11

12 leading to the simultaneous formation of 1 mol of H₂O₂ (included among ROS) and 2 mol of
13 LOP.^{23,68,69}

14 The fundamental ROS molecule is H₂O₂, which is not ionized but is an oxidant able to
15 act as an ozone messenger responsible for eliciting several biological and therapeutic
16 effects.^{70–75}

17 As it was mentioned, the old concept that H₂O₂ is always harmful has been widely
18 revised because, in physiological amounts, it acts as a regulator of signal transduction and
19 represents a crucial mediator of host defense and immune responses.^{74,76–80} While exposure
20 to oxygen is ineffective, ozone causes the generation of H₂O₂ and of the chemiluminescent
21 reaction in both physiological saline and plasma.^{47,81} However, while in saline there is a
22 consistent and prolonged increase in H₂O₂, in the ozonated plasma both chemiluminescence
23 and H₂O₂ increase immediately but decay very rapidly with a half-life of less than 2 min
24 suggesting that both antioxidants and traces of enzymes rapidly reduce H₂O₂ to water.⁴⁷ In
25 ozonated blood the reduction of H₂O₂ is so fast that it has been experimentally impossible to
26 measure it. H₂O₂ is able to easily pass through the cell membrane, but the intracellular
27 concentration increases only 1/10 of the extracellular one.^{72,74,78} Its relative stability allows
28 measuring it in plasma; in normotensive subjects its concentration is of 2.5 μM.^{70,71} In this
29 case the intracellular concentration of H₂O₂ will be at the most of 0.25 μM, while the
30 maximal intracellular concentration that can be generated for signaling purposes during the
31 ozonation process may reach 0.5–0.7 μM.⁴⁷ It appears ubiquitous as it has been detected in
32 urine and in exhaled air.⁷¹ Depending upon its local concentration and cell-type, H₂O₂ can
33 either induce proliferation or cell death.^{78,80,82,83} It can regulate vascular tone by causing
34 constrictions of vascular beds or vasodilatation although it remains uncertain if it acts as an
35 endothelium-derived hyperpolarizing factor.⁸⁴

36 A very enlightening finding was achieved by evaluating the variation of the total anti-
37 oxidant status (TAS) as measured by the Rice-Evans and Miller's method⁸⁵ in plasma after
38 ozonation and 1 min rapid mixing of the liquid–gas phases of either fresh blood or the
39 respective plasma withdrawn from the same ten donor.

40 Figure 2 shows that, after ozonation of plasma with either a medium or a high ozone
41 concentration (0.84 μmol/mL or 1.68 μmol/mL of gas per mL of plasma, respectively), TAS
42 level progressively decreases at first and then remain stable after 20 min.⁴⁷ The decrease was
43 ozone-dose dependent and varied between 46 and 63%, respectively. Conversely, TAS levels
44 in blood treated with the same ozone concentrations only decreased from 11 to 33%,
45 respectively, in the first minute after ozonation. Then they recovered and returned to the
46 original value within 20 min, irrespective of the two ozone concentrations, indicating the
47 great capacity of blood to regenerate oxidized antioxidants, namely, dehydroascorbate and
48 GSH disulfide (GSSG). Indeed, Mendiratta et al.^{66,67} have found that dehydroascorbate can
49 be recycled back to ascorbic acid within 3 min. Similarly, only about 20% of the in-
traerythrocytic GSH has been found oxidized to GSSG within 1 min after ozonation, but




Figure 2. Kinetics of TAS levels in plasma (top) and in blood (bottom) samples from donors ($n = 10$; mean + SD; unpublished results). Plasma and blood samples were exposed for 1 min either O_2 (control,) or O_2-O_3 with ozone concentrations of 40 (■) and 80 (●) $\mu\text{g}/\text{mL}$.

promptly reduced to normal after 20 min.⁸⁶ These data were enlightening and showed that the therapeutic ozonation modifies only temporarily and reversibly the cellular redox homeostasis. There is now full agreement that ascorbic acid, α -tocopherol, GSH, and lipoic acid, after oxidation, undergo an orderly reduction by a well-coordinated sequence of electron donations.⁸⁷

LOP production follows peroxidation of PUFA present in the plasma: they are heterogeneous and can be classified as lipoperoxides (LOO), alkoxy radicals (LO), lipohydroperoxides (LOOH), F_2 -isoprostanes, and alkenals, among which 4-hydroxynonenal (4-HNE), acrolein and MDA. As free radicals and aldehydes are intrinsically deleterious, only precise and appropriate ozone doses must be used in order to generate them in very low concentrations. Figure 3 comparatively shows the modifications of plasma levels of TBARS, hemolysis, TAS, and protein thiols in a typical experiment when 13 human blood samples were exposed to air, O_2 , or either 40 or 80 $\mu\text{g}/\text{mL}$ ozone concentrations. Plasma TBARS in vitro are far more stable than ROS,⁴⁷ but, upon blood reinfusion, they have a brief half-life owing to a marked dilution in body fluids, excretion (via urine and bile), metabolism by glutathione-S-transferases (GST) and aldehyde dehydrogenase (ALDH).

Among the aldehydes, 4-HNE is quantitatively the most important. It is an amphipathic molecule and reacts with a variety of compounds such as albumin, enzymes, GSH, carnosine,





Figure 3. Thirteen human blood samples were exposed to air (control), or O₂, or O₂-O₃ with ozone concentrations of 40 and 80 μg/mL for 1 min. While TBARS, TAS, and PTG levels vary significantly ($p < 0.01$) after ozone exposure, there is a negligible increase in hemolysis. (Bocci V. How does ozone act? *Oxygen-ozone therapy. A critical evaluation*, chap. 13. Figure 40. Kluwer Academic Publishers; 2002. p 114. With kind permission from Springer Science+Business Media, formerly Kluwer Academic Publishers.)

and phospholipids.^{88,89} There is no receptor for 4-HNE but Poli et al.⁸⁹ have reported that, after binding to more than 70 biochemical targets, it exerts some deleterious activity. Luckily,

1 intracellular concentrations of GSH are high enough to frequently prevent or remove 4-HNE
 2 from adducts with enzymes. Owing to the unexpected stability of 4-HNE when samples of
 3 ozonated human plasma were incubated at 37°C for 9 hr, it was postulated that ozone, for its
 4 high solubility in the plasmatic water, steric reasons, and the abundance of albumin mole-
 5 cules prefers to target their bound PUFA. The scheme presented in Figure 4 envisages the
 6 events occurring in the plasma phase. It appears reasonable that during the rapid reaction of
 7 ozone with albumin PUFA in water, the suddenly generated aldehydes, mainly 4-HNE, will
 8 immediately form adducts with contiguous albumin molecules. This hypothesis is now well
 9 supported by recent findings,⁹⁰⁻⁹² which have shown that human albumin, rich in accessible
 10 nucleophilic residues, can quench up to 11 different 4-HNE molecules, the first being with
 11 Cys34, followed by Lys199 and His146. These important data clarify why ex vivo ozonation
 12 of blood does not harm the vascular system during the infusion of ozonated blood. The
 13 albumin-4-HNE adducts, not only are rapidly diluted in the blood pool but, being trans-
 14 ferred into the extravascular pool, represent only a small aliquot of the whole albumin pool,
 15 containing as much as about 310 g protein. On this basis, it would be worthwhile exploring
 16 whether either the 4-HNE-modified albumin has an abnormal fate or how the aldehyde is
 17 released into other cell compartments, thus becoming able to trigger biochemical mechan-
 18 isms. 4-HNE is the major product of peroxidation of n-6-PUFA, its concentration in normal
 19 plasma varies from 0.07 to 0.15 μM and increases with aging.^{93,94} Needless to say that a
 20 constant increase in peroxidation as it happens after ischemia-reperfusion, CCl_4 intoxication,
 21 ADP-iron overload, and chronic inflammation typical of some infections disease, diabetes,
 22 atherosclerosis, cancer, and degenerative pathologies causes a marked increase in 4-HNE



23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49


Figure 4. The scheme helps to imagine the multiplicity of substrate reacting with ozone dissolved in plasmatic water. Small circles, triangles, and squares symbolize hydro-soluble antioxidants present in 100 mL of human blood (uric acid 4.5 mg/dL, ascorbic acid 1.5 mg/dL, glucose 80 mg/dL, etc...). Large albumin molecules (4,000 mg/dL) exposing -SH groups form a cloud over the cell membrane and protect it. Molecules such as transferrin and ceruloplasmin bind Fe^{3+} and Cu^+ and prevent formation of OH^\cdot . The exogenous addition of 4–8 mg of ozone to 100 mL of blood is transitory and controlled by antioxidants. In contrast, the endogenous production of ROS is continuous and barely quenched by intracellular antioxidants.

1 levels, especially in the affected tissues. However, aerobic organisms, for accommodating the
 2 toxicity of aldehydic compounds, have simultaneously developed detoxifying systems^{37,95–99}
 3 and their evaluation is relevant because the infusion of the ozonated blood into the donor
 4 patient implies an amount of an albumin-4-HNE adduct.

5 The following three processes schematically indicated in Figure 5 clarifies why 4-HNE is
 6 not a risk:

- 7 (1) *Dilution*: The highest concentration of 4-HNE measured after exposing 180 mL of
 8 human blood to the highest ozone amount (16 mg) is less than 1 mM in the plasma.
 9 During the 20 min intravenous infusion, the aldehyde will be promptly diluted in a
 10 total plasma-extracellular fluid volume of about 11 L, causing a transitory increase in
 11 the plasma level up to about 0.1 μ M.
- 12 (2) *Detoxification*: Metabolism of 4-HNE is extremely fast either because small amounts
 13 of aldehydes interact with billions of cells endowed with several detoxifying enzymes
 14 such as ALDH, aldose reductase, and GST or the formation of an adduct with
 15 GSH.^{36,37,98–100} Several authors^{96,101,102} have determined a metabolic rate so high to
 16 conclude that “even with very high lipid peroxidation rates, 4-HNE cannot accumulate
 17 in an unlimited way.” These data are in agreement with our results in six patients when
 18 we could assess a half-life of infused TBARS of 4.2 ± 1.7 min.^{48,49} On the contrary
 19 when the same preparation in ozonated plasma was incubated (at +37°C, pH 7.3) in
 20 acellular medium, TBARS levels hardly declined during the next 9 hr.⁴⁷
- 21 (3) *Excretion*: Partially metabolized LOP are eliminated into both bile after hepatic
 22 detoxification and urine after renal excretion. In the rat, 4-HNE was detected in the
 23 urine as mercapturic acid conjugates.^{35,98,103,104}

24 In normal conditions, owing to the efficiency of these processes, only submicromolar
 25 concentrations of LOP can reach organs such as bone marrow, endocrine glands, and even
 26 hypothalamic areas deprived of the blood–brain barrier where, via a variety of kinases and
 27 even a possible receptor for F₂-isoprostanes, may act as a signaling event of an ongoing acute
 28 oxidative stress^{105–110} (Fig. 5). As a first conclusion it is clear that the ozonation process
 29 either happening in blood ex vivo or in an intramuscular site represents an acute, albeit small,
 30



48 **Figure 5.** The multivariate biological response of the organism to ozonated blood can be envisaged by considering that
 49 ozonated blood cells and the generated LOP interact with a number of organs. Some of these represent real targets (liver in chronic
 hepatitis, vascular system for vasculopathies), while other organs are probably involved in restoring normal homeostasis. Gastro-
 intestinal tract (GIT); mucosal associated lymphoid tissue (MALT).

1 oxidative stress. However, this process is acceptable only if the ozone is precisely calibrated
 against the antioxidant capacity of either blood or the injected tissue. Moreover, the ozone
 3 dose must never lower the antioxidant capacity more than 30% with a process lasting only a
 few minutes during which ozone reacts and disappears after leaving its messengers. Thus, the
 5 process of blood ozonation *ex vivo* has been characterized by the formation of ROS and LOP
 mainly acting in two phases. Among ROS, H₂O₂ is the earliest messenger rising and
 7 disappearing within 1 min in the plasma, while LOP during drug infusion in the donor reach
 the vascular systems, act on endothelial cells, and eventually reach parenchymal cells. Their
 9 pharmacodynamics minimize their potential toxicity thus making LOP as late and effective
 messengers.


13 **B. The Effect of Ozone Messengers Onto Blood Cells**

There are two questions to be clarified: first, does ozone directly activate the cells? Our
 15 methodological approach and experimental results exclude this possibility because when
 blood is gently mixed *ex vivo* with O₂-O₃, ozone dissolves rapidly in the water of plasma and
 17 there it immediately reacts with antioxidants and PUFA. Blood cell membrane phospholipids
 surrounded by a cloud of albumin molecules do not come in contact with ozone molecules
 19 because the calculated ozone dose is rapidly exhausted (Fig. 4). This dangerous interference
 has been excluded by either a negligible hemolysis, or a change of the hematocrit value, or
 21 leakage of K⁺ and lactate dehydrogenase, or a change of osmotic fragility, or of electro-
 phoretic mobility, or increased methemoglobin.^{47,54,65,111,112} Levels (mg/dL) of fibrinogen,
 23 cholesterol, triglycerids, HDL, and LDL in plasma are not modified even using the excessive
 ozone concentration of 160 µg/mL per mL of blood.¹¹² Equally important is the stability of
 25 enzymes such as SOD, GSH-Pase, GSH-RD, and G6PDH in the erythrocytes.¹¹² Moreover,
 Shinriki et al.⁶⁵ after isolating the erythrocytic membranes after blood ozonation within the
 27 therapeutic range did neither detect a decrease in αα-tocopherol nor an increase in MDA.

It is unfortunate that in the past other authors^{57,68,113-117} have reported that erythrocytes
 29 isolated from plasma, after three washings with saline and suspension in protein-free saline,
 undergo structural changes and intense hemolysis when exposed to ozone. These misleading
 31 and unphysiological data have greatly contributed to emphasize the ozone cytotoxicity,
 which obviously was enhanced by removing plasma antioxidants.¹¹⁶ Moreover, the critical
 33 protective effect of plasma antioxidants has been emphasized in two recent studies.^{118,119}
 These results were particularly evident on saline-washed blood mononuclear cells (BMC)
 35 with a marked decrease in mitochondrial functions.¹¹⁸ Our thinking is well supported by
 other data^{47,120,121} as well as recent results (Fig. 6) obtained after excessive ozonation of
 37 samples of normal human blood either collected in heparin or in sodium citrate. Interest-
 ingly, heparinized samples were far more susceptible to ozone most likely because of the
 39 remaining physiological Ca²⁺ level: in fact, a further addition of 2.5-5 mM Ca²⁺ enhanced
 the hemolysis up to 40%.

Second, how ozone messengers activate blood cells? Initially, the sudden formation of an
 H₂O₂ gradient between the ozonated plasma and the intracellular fluid causes the rapid
 43 passage of about 10% H₂O₂ into the blood cell cytoplasm and represents the triggering
 stimulus: depending upon the cell type, different biochemical pathways can be concurrently
 45 activated in erythrocytes, leukocytes, and platelets resulting in numerous biological effects.
 The rapid reduction of H₂O₂ to water is operated by the high concentration of intracellular
 47 GSH, CAT, and GSPase but, nonetheless, H₂O₂ must be above the threshold concentration
 for activating several biochemical pathways as follows.

49 The mass of erythrocytes mops up the bulk of H₂O₂: GSH is promptly oxidized to GSSG
 and the cell, extremely sensitive to the reduction of the GSH/GSSG ratio, immediately



17 **Figure 6.** Kinetics of hemolysis in relation to ozone concentration ($\mu\text{g}/\text{mL}$ per mL of blood). Blood of five donors was treated
 18 with CPD (○) or with 30 U/mL heparin (●) (mean + SD). (Bocci V. What happens in the intracellular environment after blood ozo-
 19 nation? *Oxygen–ozone therapy. A critical evaluation*, chap. 14. Figure 43. Kluwer Academic Publishers; 2002. p 123. With kind
 permission from Springer Science + Business Media, formerly Kluwer Academic Publishers).

21 corrects the unbalance by either extruding GSSG, or reducing it with GSH-Rd at the
 22 expenses of ascorbate or of the reduced NADPH, which serves as a crucial electron donor.
 23 Next, the oxidized NADP is promptly reduced after the activation of the pentose phosphate
 24 pathway, of which glucose-6-phosphate dehydrogenase (G6PDH) is the key enzyme. In
 25 patients with ARMD, after 13 O₃-AHT, a small increase in ATP formation has been de-
 26 termined but whether this is due to the activation of the pentose cycle or to an increase in
 27 phosphofructokinase activity or to both remains to be clarified. The reinfused erythrocytes,
 28 for a brief period, enhance the delivery of oxygen into ischemic tissues because of a shift to
 29 the right of the oxygen–hemoglobin dissociation curve, due either to a slight decrease in
 30 intracellular pH (Bohr effect) or/and an increase in 2,3-diphosphoglycerate (2,3-DPG) levels
 31 as shown in Figure 7 (unpublished data). Obviously, an increase in this metabolite has a great
 32 significance because it enhances a shift to the right of the oxygenated hemoglobin, hence an
 33 increase oxygen delivery to hypoxic tissues. However, Figure 7 shows that the increase has
 34 been noted only in three patients where the initial levels were rather low. Thus, this
 35 observation needs to be explored in a large number of patients and it will be also necessary to
 36 clarify the activation of 2,3-bisphosphoglycerate mutase. Needless to say that one auto-
 37 hemotherapeutic treatment has a minimal effect and we need to ozonate at least 3–4 L of
 38 blood within a period of 30–60 days.

39 In another small group of five ARMD's patients after 15–17 O₃-AHT, an increase in
 40 some antioxidant enzymes has been determined (Fig. 8). This result has been reported also
 41 by other authors^{122,123} and it is likely that LOP act as repeated stimuli on the endothelium
 42 and bone marrow and cause the adaptation to the ozone stress during erythropoiesis.
 43 Whether the enzymatic levels remain sustained for several months during the maintenance
 44 therapy need to be evaluated.

45 Another relevant finding was that in four patients with ARMD, after a cycle of 13 O₃-AHT
 46 treatments (in which ca. 3.8 L of blood were ozonated within 7 weeks), isopycnic centrifugation of
 47 blood separated old (heavy) and young (light) erythrocytes (RBC), which showed a marked
 48 increase in G6PDH in the young erythrocytic fraction generated during the course of ozone
 49 therapy (Table I). Whether the enzymatic levels remain sustained with time need to be evaluated.
 G6PDH activity, expressed as nmol/hr/mg hemoglobin, in total red blood cells was either 357 ± 91




Figure 7. 2,3-DPG level variations in four patients performed before treatment (Basal), after 6–7 treatments (Intermediate), and at the end of treatments (Final). Insert shows the statistical dispersion (mean ± SD) of the data (unpublished results).




Figure 8. Increase in antioxidant enzymes in ARMD patients after 20–24 O₃-AHTs performed during 7–8 weeks (n = 10, mean ± SD; unpublished results).

Table I. Evaluation of G6PDH Activity in Total, Young and Old Red Blood Cells (RBC) in Blood Samples from Four Patients With Age-Related Macular Degeneration Before and After an Ozone Therapy Cycle of 13 Treatments (Unpublished Results)

	G6PDH activity ^a		
	Total RBC	Young RBC	Old RBC
Before treatment (n = 4)	356.8 ± 90.7	550.3 ± 157.5	310.7 ± 127.3
After treatment (n = 4)	406.2 ± 40.4	784.2 ± 181.9	438.8 ± 86.7

^aG6PDH activity expressed as nmol/hr/mg hemoglobin in whole erythrocyte population and in young and old fractions before and after 13 O₂/O₃ treatments. Results represent mean value ± SD.

1 or 406 ± 40 , before and after the ozone therapy, respectively. While the enzymatic increase in the whole erythrocyte population was understandably small, it was found markedly enhanced from
3 550 ± 157 to 748 ± 182 in very young (light) erythrocytes before and after ozone therapy, respectively. In the so-called old erythrocytes, which practically include the bulk of cells (20–120 days
5 old), G6PDH obviously increased only from 310 ± 127 up to 435 ± 87 nmol/hr/mgHb. It is necessary to mention that the percentage of either young or old erythrocytes remained practically
7 constant throughout the treatments (unpublished data). As a consequence, a patient with chronic limb ischemia (Phase II) undergoing ozone therapy shows a clinical improvement due to the
9 formation of successive cohorts of erythrocytes progressively more capable of delivering oxygen to his ischemic tissues.

11 Although ozone is one of the most potent disinfectants, it has been shown^{124,125} that ozone cannot inactivate bacteria, viruses, and fungi in vivo because, paradoxically, the pathogens are well protected, particularly inside the cells, by the powerful antioxidant system. Thus, the favorable effect of ozone therapy in some infectious diseases has been interpreted
13 as due to ozone acting as a mild enhancer of the immune system, by activating neutrophils and stimulating the synthesis of some cytokines.^{64,76,77,79,86,126,127} Once again the crucial
15 messenger is H_2O_2 that after entering into the cytoplasm of BMC, by oxidizing selected cysteines, activates a tyrosine kinase, able to phosphorylate the transcription factor NF- κ B.
17 The release of an heterodimer, via effector genes, causes the synthesis of several proteins, among which, the acute-phase reactants, adhesion molecules, and numerous pro-inflammatory cytokines. This process, checked by a phosphatase or inhibited by cytoplasmic
19 antioxidants, is very transitory. The release of several cytokines from ozonated blood upon in vitro incubation has been measured since 1990.¹²⁸ Once the ozonated leukocytes return into the circulation, they home in lymphoid microenvironments and successively release cytokines
21 acting in a paracrine fashion on neighboring cells with a possible reactivation of a depressed immune system. This process, described as the physiological cytokine response,¹²⁹ is a part of the innate immune system and helps us to survive in a hostile environment. One of our most
23 interesting result has consisted in observing the variable individual production of IL-8 by blood donors in 13 blood ozonated samples.¹³⁰ Figure 9 shows that the different release of IL-8 by medium and high ozone concentrations indicates the presence of high, medium, and
25 no responders. The result was interpreted as due to both genetic factors and variable levels of plasma antioxidants.

33 During ozonation of blood, particularly if it is anticoagulated with heparin, an ozone-dose-dependent increase in activation of platelets has been noted^{131,132} with a consequent
35 release of typical growth factors, which will enhance the healing of chronic ulcers in ischemic patients (Fig. 10). Whenever possible, albeit with caution, the use of heparin as an anticoagulant is preferable to sodium citrate because, by not chelating plasmatic Ca^{2+} , reinforces
37 biochemical and electric events.

39 Finally, during the reinfusion of the ozonated blood into the donor, the vast expanse of the endothelial cells is activated by albumin-LOP resulting in an increased production of NO, plasma *S*-nitrosothiols, and *S*-nitrosohemoglobin.^{133–136} Figure 11 shows the in vitro production of nitrite by human vascular endothelial cells after addition of human ozonated
41 serum. Production of NO· was markedly enhanced by the addition of L-arginine (20 μ M) and was potentiated by O_3 , while it was inhibited in the presence of the NO· inhibitor *N*- ω -nitro-L-arginine-methyl ester (L-NAME). While NO has a half-life of less than 1 sec, protein-bound NO can exert vasodilatation also at distant ischemic vascular sites with relevant
43 therapeutic effect. There is little doubt that the therapeutic advantage observed in many patients with peripheral obstructive arterial disease (POAD) is due to multiple factors such as
45 an increased release of oxygen due to vasodilation by trace amounts of NO and CO, and an increased availability of growth factors from platelets.
47
49




Figure 9. Effect of 1 min exposure of either O₂ or O₃ (40 and 80 µg/mL) on the production of IL-8 after 8 hr incubation of 13 blood samples. Average values are reported in the lower panel after subtraction of control values. *Significant difference ($p < 0.01$) compared with samples treated with O₂. The variable production of IL-8 among donors is noteworthy, particularly the lack of production of donors no. 3 and 12 likely due to a high TAS level. (Bocci V. What happens in the intracellular environment after blood ozonation? *Oxygen-ozone therapy. A critical evaluation*, chap. 14. Figure 53. Kluwer Academic Publishers; 2002. p 134. With kind permission from Springer Science+Business Media, formerly Kluwer Academic Publishers).

All of these data emphasize that submicromolar LOP levels can be stimulatory and beneficial,¹³⁷ while it is well established that micromolar levels can be toxic.⁸⁹ This conclusion reinforces the concept that optimal ozone concentrations are critical for achieving a therapeutic result: too low concentrations are practically useless (at best elicit a placebo effect), too high may elicit a negative effect (malaise, fatigue), so that they must be just above the threshold level to yield an acute, absolutely transitory oxidative stress capable of triggering biological effects without toxicity. There is no doubt that the process of blood ozonation must be precisely controlled with a calculated ozone dosage: at this condition it is not deleterious and actually capable of eliciting a multitude of useful biological responses and, possibly, reversing a chronic oxidative stress due to ageing, chronic infections, and the several diseases grouped within the metabolic syndrome. Indeed the ozonotherapeutic act has been interpreted as a safe “therapeutic shock” able to restore homeostasis.¹³⁸ These aspects are critical and imply two drawbacks: first, if the ozone generator is not well calibrated or periodically checked, it may release erroneous and dangerous ozone amounts and, second, if the ozonotherapist does not fully understand the ozonation process, he may do some mistakes and jeopardize the approach. Other aspects regarding the future of ozone therapy will be evaluated in Section 9.

5. IS OZONE ABLE TO INDUCE AN ADAPTATION TO CHRONIC OXIDATIVE STRESS?

That ozone, one of the most potent oxidizer, may induce an antioxidant response capable of reversing a chronic oxidative stress at first sight seems a paradoxical concept. However, this




Figure 10. Release of factors from human platelets during 1, 2, and 4 hr incubation. The same PRP samples collected either in heparin or ACD were not exposed (control), or exposed to O₂ alone or to O₂-O₃ at concentrations of 20, 40, and 80 μg/mL for 30 sec before incubation. Statistical significance is indicated by (*) for intergroup analysis and (+) for intragroup analysis. (Bocci V. What happens in the intracellular environment after blood ozonation? *Oxygen-ozone therapy. A critical evaluation*, chap. 14. Figure 65. Kluwer Academic Publishers; 2002. p 158. With kind permission from Springer Science+Business Media, formerly Kluwer Academic Publishers).




Figure 11. Production of nitrite by HUVECs, measured after 24 hr incubation, after addition of normal human serum either oxygenated or ozonated (at 40 and 80 μg/mL). Effects of addition of L-arginine and L-NAME. The data are presented as the mean + SD of six different experiments. (Bocci V. What happens in the intracellular environment after blood ozonation? *Oxygen-ozone therapy. A critical evaluation*, chap. 14. Figure 68. Kluwer Academic Publishers; 2002. p 165. With kind permission from Springer Science+Business Media, formerly Kluwer Academic Publishers).

1 concept has become common in the animal and vegetal kingdoms.¹⁴⁷⁻¹⁵⁰ Any change of the
 2 external or internal environment disturbs cell homeostasis, but if the stress is tolerable, or
 3 carefully calibrated in intensity, the cell or the organism can adapt to it and survive. If it is
 4 excessive or the cell is already damaged, the cell programmes its own death. Stresses include
 5 hyperthermia, hyperoxia, ischemia, hypoglycemia, pH modifications, radiation, very likely
 6 mental and hormonal derangement, and chronic infections, which imply an excessive ROS
 7 and LOP production. Obviously, ozone has to be included and the phenomenon of ozone
 8 tolerance is now well known. The concept of “ischemic preconditioning” for the heart, which
 9 after undergoing a brief, nonlethal period of ischemia can become resistant to infarction from
 10 a subsequent ischemic insult was pioneered by Murry et al.¹⁵¹ “Oxidative preconditioning”
 11 has been also well demonstrated.¹⁵²⁻¹⁵⁷ Therefore, it is of interest that small amounts of ROS
 12 and LOP can elicit the upregulation of antioxidant enzymes on the basis of the phenomenon
 13 described under the term of “hormesis.”¹⁵⁸⁻¹⁶² On the basis of this phenomenon that says
 14 “the exposure of an organism to a low level of an agent, harmful at high levels, induces an
 15 adaptive and beneficial response,”^{159,160,163} it has been postulated that LOP, by acting as
 16 long-distance messengers, can transmit to all organs the information of an acute oxidative
 17 stress.⁵⁴ The bone marrow is particularly relevant because it can upregulate antioxidant
 18 enzymes during erythropoiesis and may allow the release of stem cells for possibly
 19 regenerating infarcted organs.

20 The oxidative preconditioning or, as we prefer, the adaptation to the chronic oxidative
 21 stress has been now demonstrated experimentally.^{40,45,48} The increased synthesis of enzymes
 22 such as SOD, GSPase, GSH-Rd, and CAT has been repeatedly determined in experimental
 23 animals and in patients (reviewed in 57). Iles and Liu¹⁶⁴ have demonstrated the 4-HNE, by
 24 inducing the expression of γ -glutamyl cysteine ligase, causes an intracellular increase in
 25 GSH, which plays a key role in antioxidant defence. Furthermore LOP induce oxidative
 26 stress proteins, one of which is heme-oxygenase I (HO-1 or HSP-32) that, after breaking
 27 down the heme molecule, delivers very useful compounds such as CO and bilirubin.¹⁶⁵⁻¹⁷¹
 28 Bilirubin is a significant lipophilic antioxidant and a trace of CO cooperates with
 29 NO in regulating vasodilation by activating cyclic GMP. Fe^{2+} is promptly chelated by the
 30 upregulated synthesis of ferritin.¹⁷² The induction of HO-1 after an oxidative stress
 31 has been described in thousands of papers as one of the most important antioxidant
 32 defence and protective enzyme. Both mild ozone inhalation and ozonated plasma
 33 induce HSP-70.^{170,173} When ozone is judiciously used in small doses, can become a
 34 useful drug able to correct an otherwise irreversible state of oxidative stress. There are
 35 serious pathologies such as chronic infections, neurodegenerative, and autoimmune
 36 diseases in which a vicious imbalance between overproduced oxidants and depleted
 37 antioxidant defenses become established and lead to death. How modern medicine correct
 38 this imbalance? Several therapeutic approaches among which administration of antioxidants
 39 with addition of *N*-acetylcysteine have been often reported¹⁷⁴⁻¹⁷⁶ but they are only partly
 40 successful.

41 The ozone treatment is now envisaged as a transitory and miniaturized oxidative stress
 42 resulting in a sort of therapeutic “shock” for the ailing organism. Ozone acting as a prodrug,
 43 realizes this shock because generates a number of messengers able to reach all cells in the
 44 organism (Fig. 5).

45 Submicromolar levels of LOP act as key mediators and in still responsive cells may
 46 activate a sequence of biochemical mechanisms able to reactivate gene expression leading to a
 47 renewed synthesis of HSP and antioxidant enzymes. If the disease has gone too far, cells
 48 become anergic and are unable to respond to the treatment. Indeed, we have observed that
 49 after intensive chemotherapy, preterminal cancer patients do not improve with ozone ther-
 50 apy. That is also the reason why we always start using low ozone concentrations just above

1 the threshold level to better achieve the ozone tolerance and in-line with the old concept
 3 “start low, go slow.” Moreover, the stimulation of the endocrine and central nervous systems
 5 may help to understand why most of the reactive patients during prolonged ozone therapy
 7 report a feeling of euphoria and wellness probably due to an improved metabolism as well as
 9 to an enhanced hormonal or neurotransmitters release.

9 6. WHICH ARE THE ROUTES OF OZONE ADMINISTRATION?

11 Table II shows that ozone can be administered with great flexibility but it should never be
 13 injected intravenously as a gas because of the risk of provoking oxygen embolism, given the
 15 fact that the gas mixture contains always no less than 95% oxygen. So far the most advanced
 17 and reliable approach has been the O₃-AHT because, on the basis of the patient’s body
 19 weight, a predetermined volume of blood (200–250 mL) to which has been added either
 21 sodium citrate 3.8% (1+9 mL blood) or heparin (20 IU/mL of blood) can be exposed to an
 23 equal volume of gas (O₂–O₃) in a stoichiometric fashion, with the ozone concentration pre-
 25 cisely determined by using an ozone-resistant, disposable 500 mL glass bottle *under vacuum*.

19 This simple, inexpensive (all the necessary disposable material costs about 12 US\$)
 21 procedure has already yielded therapeutic results in vascular diseases superior to those
 23 achieved by conventional medicine (discussed in Section 7A). Moreover, the therapeutic
 25 modalities, until now restricted to major AHT and to the empirical and imprecise rectal
 27 insufflation of gas,^{139,177,178} have been extended: they include the quasi-total body exposure
 29 to O₂–O₃^{140,179} and the extracorporeal blood circulation against O₂–O₃.¹⁴¹ The latter
 31 procedure is rather invasive because blood collected from a vein circulates through an
 33 ozone-resistant gas exchanger^{180,181} and, with the help of a peristaltic pump, returns to the
 35 circulation via a contralateral vein. On the other hand, the partial cutaneous exposure to
 37 oxygen–ozone does not need any venous puncture and, owing to the vast expanse of the skin,
 39 allows a generalized and beneficial effect. Clearly, today we can select the most suitable
 41 method for different pathologies, their stage, and the patient’s condition. A discussion on its
 43 own is needed for the minor AHT, which basically consists of withdrawing 5 mL of blood to
 45 be immediately and vigorously mixed for 1 min with an equal volume of O₂–O₃ at an ozone

35 **Table II.** Routes of Ozone Administration

37 Parenteral	Topical or locoregional
39 Intra-arterial (IA) ^a	Nasal ^b
41 Intramuscular (IM)	Tubal ^b
43 Subcutaneous (SC)	Auricular
45 Intraperitoneal (Ipe)	Oral ^b
47 Intrapleural (IPL)	Vaginal
Intra-articular (IPL)	Urethral and intrabladder
(a) Periarticular	Rectal
(b) Myofascial	Cutaneous
Intradiscal (ID)	Dental
Intraforaminal (IF)	
Intralesional (Iles) ^c	

49 ^aNo longer used for limb ischemia. Hepatic metastasis could be embolized via the hepatic artery.

^bTo be performed during 30–40 sec apnea.

^cIntratumoral or via a fistula.

1 concentration ranging between 80 and 100 $\mu\text{g}/\text{mL}$ of gas per mL of blood already extensively
 2 described.¹⁴² The slightly oxidized blood, including the foam, is promptly injected into the
 3 gluteus muscle without the need of any anesthetic. As an unspecific immunomodulatory
 4 approach, it has been widely used during the last two decades for successfully treating
 5 herpetic infections.¹⁴³

6 The slight hemolysis ($\sim 2\%$) is purposefully required because the heme released in the
 7 gluteal muscle will stimulate the synthesis of HO-1.^{165,171}

9

11 **7. WHICH DISEASES ARE SUITABLY TREATED WITH OZONE THERAPY**

11

12 On the basis of the mechanisms of action, ozone therapy can induce the following biological
 13 responses: (a) it improves blood circulation and oxygen delivery to ischemic tissue owing to
 14 the concerted effect of NO and CO and an increase in intraerythrocytic 2,3-DPG level; (b) by
 15 improving oxygen delivery, it enhances the general metabolism; (c) it upregulates the cellular
 16 antioxidant enzymes and induces HO-1 and HSP-70; (d) it induces a mild activation of the
 17 immune system and enhances the release of growth factors; (e) it has an excellent disinfectant
 18 activity when topically used, while this is negligible in the circulation owing to blood anti-
 19 oxidant capacity; (f) it does not procure acute or late side effects;¹⁸² (g) it procures a sur-
 20 prising wellness probably by stimulating the neuro-endocrine system. It does seem that
 21 ozone, by acting on many targets, can indirectly help in recovering functional activities gone
 22 astray because of a chronic disease and, if this interpretation is correct, ozone therapy acts as
 23 a biological response modifier. Although ozone therapy is now used in many countries, it is
 24 mostly used by private physicians and the performance of large clinical trials has been
 25 severely hampered by lack of sponsors, disinterest of pharmaceutical as well as health
 26 authorities, and prejudice by clinical scientists. However, a number of studies have been
 27 performed with the following results:

29

30 **A. Peripheral Obstructive Arterial Diseases**

31 Even a modest obstruction of limb arteries due to atherosclerosis, diabetes, or Buerger's
 32 disease (thromboangiitis obliterans) leads to a progressive reduction of blood flow to the feet.
 33 Tissue ischemia and any minor trauma facilitate the formation of an ulcer, which will not
 34 heal because oxygen, nutrients, and growth factors indispensable for the repair process are
 35 lacking. This pathology is the best suited to be treated with O₃-AHT. According to Fontaine-
 36 Leriche classification, patient at either stage II (intermittent claudication and transitory
 37 pain), or stage III (continuous pain, cyanosis, and possibly initial ulcers) achieve the best
 38 results. Stage IV includes incipient necrosis of toes and unbearable pain leads to surgical
 39 amputation that can be avoided with O₃-AHT in about 50% of cases.¹⁸³⁻¹⁸⁵ In comparison
 40 to pentoxifylline and prostanooids (the gold standard of orthodox treatment), O₃-AHT has
 41 proved more effective and without side effects in ischemic vascular disease. In a small trial, 28
 42 patients were randomized to either receive their own ozonated blood or an IV infusion of
 43 prostacyclin.¹⁸⁶ All patients continued conventional treatment with statins, antihypertensive,
 44 and antiplatelet aggregation drugs. Ozone therapy proved more effective than prostacyclin in
 45 terms of pain reduction and improvement in the quality of life, but no significant difference
 46 was seen in vascularization of the lower limbs in either group, most likely due to the short
 47 duration of treatment (14 treatments in 7 weeks). More prolonged treatments lead to a
 48 satisfactory healing of ulcers.¹⁸⁷ Previous studies^{122,188-194} have shown the validity of
 49 O₃-AHT in this complex pathology, but it is a mistake to stop therapy too early in these
 patients because O₃-AHT, as with other conventional drugs, must be continued, albeit less

1 frequently, for life. An improved schedule on a trial in progress consists of two O₃-AHT
 (225 mL blood plus 25 mL 3.8% sodium citrate solution), given weekly for at least 4 months.
 3 Topical therapy performed with ozonated olive oil is extremely useful when initial dry
 gangrene or ulcers are present. The frequency of O₃-AHT depends upon the stage of the
 5 disease and regarding the III and IV stages it can be done every day in the attempt to prevent
 amputation. How well O₃-AHT works it appears evident by the fact that the nocturnal
 7 excruciating pain disappears after the first two to three treatments, indicating the improve-
 ment of blood flow in the ischemic tissue and the lack of “stealing” blood away from
 9 underperfused muscle.

On January 2008, the Lancet published a double-blind, placebo controlled study
 11 (ACCLAIM trial) in 2,426 patients with New York Heart Association (NYHA) functional
 classes II–IV chronic heart failure (CHF).¹⁹⁵ Beside standard medication, the experimental
 13 group during a period of some 24 weeks, underwent about 25 intragluteal injections each
 patient receiving 10 mL of its own blood heavily oxidized with ozone associated with UV
 15 irradiation and heating at 42.5°C. It is unbelievable that 10 mL of blood were oxidized with as
 many as 75 mg of ozone, a dose that kills all cells and denature plasma proteins. This
 17 procedure, which is a sort of minor O₃-AHT,¹⁹⁶ had been invented with the aim to produce
 immunosuppressive compounds able to counteract the pathophysiological mechanisms
 19 responsible for the progression of CHF. Results have been disappointing because no dif-
 ference in the composite endpoint of death for cardiovascular reasons between the control
 21 and the experimental group were noted. A few researchers^{197–200} have criticized the approach
 that had been also a failure in the previous Simpadico trial in patients with chronic limb
 23 ischemia.²⁰¹ Actually this trial was stopped because of the risk of inducing neoplasia. This
 approach has been discussed here because, being based on an irrational concept, may
 25 undermine the progress of the real O₃-AHT that utilizes the minimal amount of ozone just
 sufficient for triggering useful biological activities.

27 Millions of people suffer from chronic limb, brain, and heart ischemia, which represent
 the major cause of death worldwide. This has a huge socio-economic impact, particularly in
 29 the developing world. If only orthodox medicine will accept O₃-AHT as an adjunct to
 standard medication, a great leap forward will be noted.

31

33 **B. Age-Related Macular Degeneration**

In the UK alone, some 200,000 patients affected by the “dry” (atrophic) form of ARMD are
 35 suitable for treatment with O₃-AHT,²⁰² but all over the world there are about 30 million
 people searching for a therapy. Nonetheless, ophthalmologists can only prescribe anti-
 37 oxidants and zinc, which are minimally effective.^{203,204} Since 1995, almost 1,000 patients with
 the dry form of ARMD have been treated with O₃-AHT at our polyclinic and three-quarters
 39 have shown an improvement of one to two lines on the visual acuity chart.^{144,205}

Usually 15–18 treatments, at an initial ozone concentration of 20 µg/mL of gas per mL
 41 blood, slowly upgraded to 60 µg/mL (twice weekly), followed by two monthly session as a
 maintenance therapy, allows to maintain the improvement. Although uncontrolled, this
 43 study emphasizes that O₃-AHT is the only treatment able to dramatically improve the pa-
 tient’s quality of life. In this disease there is progressive degeneration and death of the fovea
 45 centralis photoreceptors and of the pigmented retinal epithelium (PRE) as a consequence of
 several factors, one of which is chronic hypoxia. Although O₃-AHT induces a pleiotropic
 47 response, the main advantage is due to an increased delivery of oxygen to the retina, which is
 the bodily tissue with the highest oxygen consumption. It is worth noting that O₃-AHT is
 49 useless, even harmful, in the exudative form of ARMD and in multigenic and progressive
 disorders (e.g., retinitis pigmentosa and recessive Stargardt’s disease).²⁰⁶ The exudative form,

1 characterized by an aberrant choroidal vascular growth and a vascular hyperpermeability
 2 beneath the retina and the PRE, is caused by worsened ischemia, which negatively stimulates
 3 the release of the vascular endothelial growth factor. It must be emphasized that O₃-AHT (in
 4 the dry form) not only improves visual activity but at least, in part, renders the patient
 5 capable of autonomous life.

7 **C. Chronic Infectious Diseases**

9 Ozone is regarded as the best topical disinfectant because bacteria, viruses, fungi, and pro-
 10 tozoa, when free in water, are readily oxidized.^{207,208} Disappointingly, destruction of free
 11 pathogens in plasma by ozone either *ex vivo* or *in vivo* is greatly hampered by soluble
 12 antioxidants such as albumin, ascorbic acid, and uric acid and they are virtually unassailable
 13 when there are intracellular located.^{124,125} However, ozone therapy still deserves attention
 14 because, by improving metabolism and operating as a mild cytokine inducer,⁶⁴ it can have a
 15 beneficial influence on infectious diseases. Thus, there remains a place for the application of
 16 O₃-AHT as an adjuvant in chronic viral infections (e.g., HIV, HCV, HSV), in combination
 17 with highly active anti-retroviral therapy (HAART), pegylated interferon- α plus either
 18 lamivudine or ribavirin and the acyclovir.

19 On the other hand, bacterial septicaemia must be treated with the most suitable anti-
 20 biotics to prevent toxemia and multisystem organ dysfunction. Particularly important is the
 21 topical application of either (i) ozone as a gas mixture (about 4% ozone and 96%
 22 oxygen);^{209,210} or (ii) as ozonated water; or (iii) ozonated oils (where ozone is firmly stabilized
 23 as a triozone)^{208,211–214} for the treatment of bacterial, viral, and fungal infections, aphthous
 24 ulcers, burns, abscesses, and osteomyelitis. Topical therapy is most effective when combined
 25 with O₃-AHT owing to the improved oxygenation of hypoxic tissues. Radiodermatitis²¹⁵ and
 26 wound healing have been enhanced because ozonated solutions display a cleansing effect, act
 27 as a disinfectant, and stimulate tissue reconstruction. A recent review reports that the high
 28 rates of diabetes in many parts of the world make foot ulcers a major and increasing public-
 29 health problem. Foot ulcers cause substantial morbidity, impair quality of life, engender high
 30 treatment costs (about US\$17,500–27,987) and are the most important risk factor for lower-
 31 extremity amputation.²¹⁶ Although the constant use of rectal–colon insufflation of O₂–O₃ is
 32 not the optimal approach, it seems to improve the prognosis of diabetes by combining topical
 33 therapy with ozonated oil and O₃-AHT.²¹⁷ This study needs to be confirmed. Ozonated olive
 34 oil is an amazing preparation because combines antibacterial activity with healing properties
 35 due to the slow release of oxygen in hypoxic tissues and the stimulation of fibroblasts
 36 proliferation.^{212,213} Chronic ulcers and/or putrid wounds are one of the most distressing and
 37 difficult medical problems with which to deal and are caused by ischemia, diabetes,
 38 immunosuppression, and malnutrition. During the past decade the use of ozone derivatives
 39 in such cases has proved very beneficial,¹⁴³ but so far official medicine has not yet discovered
 40 this excellent preparation far more effective than ointments containing often ineffective anti-
 41 biotics and corticosteroids, which delays healing. With the current increase in health-care
 42 costs, O₃-AHT and ozonated oils deserve attention because they reduce hospital assistance
 43 and are inexpensive.

45 **D. Pulmonary Diseases**

46 Lung diseases, such as chronic obstructive pulmonary disease (COPD), will soon become the
 47 fourth most common cause of death, which, with emphysema and asthma, make significant
 48 incapacity. Using corticosteroids, long-acting β_2 -agonists, and antibiotics, orthodox medicine
 49 has certainly proved helpful,²¹⁸ but it cannot change the course of COPD. However, in a
 series of elderly patients affected by macular degeneration and either emphysema or COPD,

1 a remarkable improvement has been observed by combining ozone therapy²¹⁹ (using the
 2 schedule adopted for vasculopathies) with the best conventional treatments. It is unfortunate
 3 that so far a randomized study evaluating orthodox therapy with or without O₃-AHT has not
 4 been performed.

5

6 ***E. The versatility of Ozone Application in Orthopaedics and Dentistry***

7

8 The application of ozone in low back pain has proved very effective. It can be administered
 9 directly (intradiscal),²²⁰⁻²²⁴ or indirectly, via intramuscular administration into the para-
 10 vertebral muscles. This latter type of administration has been assimilated to a “chemical
 11 acupuncture.”¹⁴⁵ During the last 6 years, more than 30,000 patients with hernial disc have
 12 been treated in Italy with a success rate varying from 62 to 80%. The value of this approach,
 13 minimally invasive and without risk, has been already recognized in several countries, from
 14 China to Spain and South America. As shown also in another study on pain-related disorders
 15 due to sport injury (232 subjects) and inflammatory disorders (770 subjects)²²⁵ it appears that
 16 ozone exerts a multiplicity of effects, such as the activation of the anti-nociceptive system,
 17 and it has anti-inflammatory action due to lipid peroxidation products, with the consequent
 18 inhibition of cyclooxygenase-2 (COX-2).^{226,227}

19 Finally, ozone has proved very useful in dentistry for eliminating infections and blocking
 20 primary root carious lesions.^{228,229} The interested reader will appreciate the notable book
 21 “*Ozone: the revolution in dentistry*.”²³⁰ After almost 80 years the intuition of Dr. Fisch could
 22 not receive a more enthusiastic appreciation by Prof. Lynch.

23

24 ***8. IS OZONE THERAPY A BAD COPY OF HYPERBARIC OXYGEN THERAPY?***

25 It is often thought that ozone therapy tries to simulate the advantages of the much better
 26 known hyperbaric oxygen therapy (HOT)²³¹⁻²³³ and therefore it seems useful to clarify that
 27 these two approaches are both theoretically and practically different.

28 In the former, the drug is represented by ozone and, while we have described its initial
 29 reaction and the cascade of active messengers, it has also been pointed out that oxygenation
 30 of blood is not its primary intent. Conversely, by breathing almost pure oxygen at 2.6 bar
 31 into the hyperbaric chamber, the volume of dissolved oxygen in the plasma increases up to
 32 about 5 mL/dL, that is enough to satisfy ischemic tissues even if the absence of fully
 33 oxygenated hemoglobin. HOT is only transitorily effective because after 2 hr of therapy,
 34 hypoxia resumes in ischemic tissues and therefore the therapeutic effect is temporary.
 35 However, HOT has an exclusive role in CO-poisoning, air embolism, decompression
 36 sickness, and perhaps clostridial myonecrosis while ozone therapy is far more effective and
 37 practical to perform in POAD, heart ischemia, ARMD, diabetic foot, chronic ulcers, and
 38 bedsores. Thus, both approaches are relevant but each one has its selected field of application
 39 and the difference should be understood for the sake of the patient.¹⁴⁶

40

41 ***9. CONCLUSIONS***

42

43 The history of medicine remind us that in the past the application of several important
 44 approaches has been delayed owing to prejudice, lack of knowledge, or of sponsors and often
 45 by commercial competition. Ozone is inexpensive and therefore ozone therapy does not make
 46 an exception in spite of the fact that all chemical, biochemical, physiological, and pharma-
 47 cological mechanisms elicited by ozone as primum movens are in the realm of orthodox
 48 medicine.

1 medicine. One wonders if now with the advent of molecular medicine and gene therapy,
2 ozone therapy is obsolete or worthwhile being pursued. Our many treated patients answer for
3 us by saying that it is very beneficial. The compliance is excellent and the patients, as soon as
4 the therapeutic effect declines, ask for a new cycle, showing the benefit and lack of side
5 effects. It has been unfortunate that, in the past, the direct intravenous injection of the gas,
6 now prohibited, the use of primordial ozone generators and misuse of ozone by incompetent
7 quacks has generated serious doubts about its validity. Moreover, pulmonary toxicity due to
8 prolonged inhalation of polluted air and many nonphysiological studies, performed in saline
9 washed erythrocytes unprotected by the potent plasma antioxidants, have generated the
10 dogma that ozone is always toxic and should not be used in medicine. This concept cannot be
11 generalized because it does not take into account the profound difference between the en-
12 dogenous chronic oxidative stress, due to aging or to a chronic disease, and the calculated,
13 extremely brief, and well-calibrated oxidative stress induced on blood by using a precise and
14 small ozone dose. When the appropriate ozone dose reacts with biomolecules it yields a
15 number of compounds that in spite of their intrinsic toxicity, thanks for their pharmaco-
16 dynamic, stimulate important biochemical pathways. Indeed, the medical effect depends
17 upon a critical balance between an appropriate small dose of ozone and an almost infinite
18 reacting variables such as the multiplicity of antioxidants, the life-time of ROS and LOP,
19 their in vivo pharmacokinetic, and most important the variability of the biological response
20 depending upon on enzyme reactivity and the stage of the disease.

21 Since the discovery of NO as a physiological messenger, other gaseous molecules such as
22 CO, H₂S, and H₂,²³⁴⁻²³⁶ in spite of being known as potentially toxic molecules, if used
23 judiciously are now considered as possible therapeutic agents. Any drug, depending upon its
24 dosage can be either therapeutic or toxic. A striking example is represented by a vital
25 compound such as glucose, its normal concentration in the plasma ranges between 0.7 and
26 1.0 mg/mL. However, when this concentration falls below 0.4 mg/mL, the consequent hy-
27 poglycemic coma can be deadly. On the other hand, if the glucose concentration remains
28 constantly above 1.3 mg/mL, it induces the metabolic syndrome, which is well exemplified by
29 the current diabetic epidemic. Finally, oxygen at 21% concentration in air (and an arterial
30 pO_2 of about 99 mmHg) allows us to live for almost 80 years but it is deadly if we breathe
31 pure oxygen for a few days. Thus, while a further discussion regarding ozone toxicity in
32 medicine appears futile, it is important to examine if, indeed ozone therapy will be able to
33 acquire a right place among the medical armamentarium. In the last decade, ozone therapy
34 has attracted great attention in less-developed countries, while it remains partly prohibited in
35 USA and poorly regarded in other developed countries. What can be done to change this
36 severe outlook? Today we have a comprehensive framework for understanding the bio-
37 chemical mechanisms and the biological effects of ozone and we have at least in part the
38 capability of recommending ozone therapy in selected diseases either as a first choice or even
39 better in combination with orthodox therapy. Thus, first, we must continue to organize
40 specialized courses for physicians for avoiding conceptual or technical pitfalls. Second, while
41 it is important to continue specific biologic studies, it is imperative to perform controlled and
42 extensive clinical trials to prove beyond any doubt the value of ozone therapy at least in
43 vascular diseases. Unless this is done, there is no future for ozone therapy within official
44 medicine. The stumbling block is represented by lack of sponsors, disinterest of the phar-
45 maceutical industry, and negligence of health authorities. As ozone therapy is a very cheap
46 treatment, especially if it will be performed in all hospitals on a daily basis, it will markedly
47 reduce both medical cost and invalidity. Almost needless to say that ozone therapy, like
48 orthodox medicine, cannot “cure” several human diseases such as ARMD, atherosclerosis,
49 and metabolic diseases. However, the maintenance therapy associated with conventional
50 medication could improve the life of many patients. By considering the huge cost of reliable

1 controlled and randomized clinical trials, unless health authorities give a financial support,
 2 ozone therapy will remain in limbo and in the hands of private physicians who can only
 3 report anecdotal and yet useless data. Only scientifically well-demonstrated therapeutic
 4 advantages will be able to dissipate prejudice and allow oxygen–ozone therapy to become a
 5 world wide useful medicinal treatment.

7

9 **ACKNOWLEDGMENTS**

10 One of us (V.B.) is grateful to the University of Siena for the permission to continue to work
 11 in the Department of Physiology as Emeritus Professor of Physiology. We are grateful and
 12 thank Mrs. Helen Carter for revising the English manuscript.
 13

15

16 **REFERENCES**

17

19

21

23

25

27

29

31

33

35

37

39

41

43

45

47

49

1. Burns DT. Early problems in the analysis and the determination of ozone. *Fresenius J Anal Chem* 1997;357:178–183.
2. Rubin MB. The history of ozone. The Schönbein period, 1839–1868. *Bull Hist Chem* 2001;26:40–56.
3. Battino R. Oxygen and ozone. IUPAC solubility data series. Vol. 7. Oxford, UK: Pergamon Press; 1981.
4. Kogelschatz U, Eliasson B, Hirth M. Ozone generation from oxygen and air: Discharge physics and reaction mechanisms. *Ozone Sci Eng* 1988;10:367–378.
5. Tanaka T, Morino Y. Coriolis interaction and anharmonic potential function of ozone from the microwave spectra in the excited vibrational states. *J Mol Spectrosc* 1970;33:538–551.
6. Babior BM. Oxygen-dependent microbial killing by phagocytes (first of two parts). *N Engl J Med* 1978;298:659–668.
7. Babior BM. Oxygen-dependent microbial killing by phagocytes (second of two parts). *N Engl J Med* 1978;298:721–725.
8. Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. *Free Radic Biol Med* 2007;42:153–164.
9. Wentworth Jr P, Wentworth AD, Zhu X, Wilson IA, Janda KD, Eschenmoser A, Lerner RA. Evidence for the production of trioxigen species during antibody-catalyzed chemical modification of antigens. *Proc Natl Acad Sci USA* 2003;100:1490–1493.
10. Wentworth Jr P, Nieva J, Takeuchi C, Galve R, Wentworth AD, Dilley RB, DeLaria GA, Saven A, Babior BM, Janda KD, Eschenmoser A, Lerner RA. Evidence for ozone formation in human atherosclerotic arteries. *Science* 2003;302:1053–1056.
11. Smith LL. Oxygen, oxysterols, ouabain, and ozone: A cautionary tale. *Free Radic Biol Med* 2004;37:318–324.
12. Heng S, Yeung KL, Djafer M, Schrotter J-C. A novel membrane reactor for ozone water treatment. *J Membr Sci* 2007;289:67–75.
13. Rozema J, Björn LO, Bornman JF, Gaberik A, Häder D-P, Trot T, Germ M, Klisch M, Gröniger A, Sinha RP, Lebert M, He Y-Y, Buffoni-Hall R, de Bakker NVJ, van de Staaij J, Meijkamp BB. The role of UV-B radiation in aquatic and terrestrial ecosystems—an experimental and functional analysis of the evolution of UV-absorbing compounds. *J Photochem Photobiol B* 2002;66:2–12.
14. US Environmental Protection Agency. National ambient air quality standards for ozone; final rule. Available at: http://www.epa.gov/air/ozonepollution/pdfs/2008_03_finalrule.pdf. Accessed October 13, 2008.

- 1 15. Bell ML, McDermott A, Zeger SL, Samet JM, Dominici F. Ozone and short-term mortality in 95
US urban communities, 1987–2000. *J Am Med Assoc* 2004;292:2372–2378.
- 3 16. Mortimer KM, Tager IB, Dockery DW, Neas L, Redline S. The effect of ozone on inner-city
children with asthma: Identification of susceptible subgroups. *Am J Respir Crit Care Med*
5 2000;162:1838–1845.
- 7 17. Ruidavets JB, Cournot M, Cassadou S, Giroux M, Meybeck M, Ferrieres J. Ozone air pollution is
associated with acute myocardial infarction. *Circulation* 2005;111:563–569.
- 9 18. Tager IB, Balmes J, Lurmann F, Ngo L, Alcorn S, Kunzli N. Chronic exposure to ambient ozone
and lung function in young adults. *Epidemiology* 2005;16:751–759.
- 11 19. Lippman M. Health effects of ozone, a critical review. *J Am Air Pollut Control Assoc*
1989;39:672–695.
- 13 20. Mustafa MG. Biochemical basis of ozone toxicity. *Free Radic Biol Med* 1990;9:245–265.
- 15 21. Bastacky J, Lee CYC, Goerke J, Koushafar H, Yager D, Kenaga L, Speed TP, Chen Y,
Clements JA. Alveolar lining layer is thin and continuous: Low-temperature scanning electron
17 microscopy of rat lung. *J Appl Physiol* 1995;79:1615–1628.
- 19 22. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG.
Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of
21 dilution. *J Appl Physiol* 1986;60:532–538.
- 23 23. Pryor WA. Mechanisms of radical formation from reactions of ozone with target molecules in the
lung. *Free Radic Biol Med* 1994;17:451–465.
- 25 24. Kelly FJ, Mudway I, Krishna MT, Holgate ST. The free radical basis of air pollution: Focus on
ozone. *Respir Med* 1995;89:647–656.
- 27 25. Hamilton Jr RF, Eschenbacher WL, Szweda L, Holian A. Potential involvement of
4-hydroxynonenal in the response of human lung cells to ozone. *Am J Physiol* 1998;274:L8–L16.
- 29 26. Spickett CM, Jerlich A, Panasencko OM, Arnhold J, Pitt AR, Stelmaszynska T, Schaur RI. The
reactions of hypochlorous acid, the reactive oxygen species produced by myeloperoxidase, with
27 lipids. *Acta Biochim Pol* 2000;47:889–899.
- 31 27. Cho HY, Zhang LY, Kleeberger SR. Ozone-induced lung inflammation and hyperreactivity are
mediated via tumor necrosis factor- α receptors. *Am J Physiol Lung Cell Mol Physiol*
2001;280:L537–L546.
- 33 28. Goldkorn T, Khan EM. Dual roles of oxidative stress in the lungs. In: Valacchi G, Davis P,
editors. *Oxidants in biology*. The Netherlands: Springer; 2008. pp 231–250.
- 35 29. Long NC, Suh J, Morrow JD, Schiestl RH, Murthy GG, Brain JD, Frei B. Ozone causes lipid
peroxidation but little antioxidant depletion in exercising and nonexercising hamsters. *J Appl
Physiol* 2001;91:1694–1700.
- 37 30. Montuschi P, Nightingale JA, Kharitonov SA, Barnes PJ. Ozone-induced increase in exhaled
8-isoprostane in healthy subjects is resistant to inhaled budesonide. *Free Radic Biol Med*
2002;33:1403–1408.
- 39 31. Corradi M, Alinovi R, Goldoni M, Vettori M, Folesani G, Mozzoni P, Cavazzini S,
Bergamaschi E, Rossi L, Mutti A. Biomarkers of oxidative stress after controlled human
41 exposure to ozone. *Toxicol Lett* 2002;134:219–225.
- 43 32. Last JA, Gohil K, Mathrani VC, Kenyon NJ. Systemic responses to inhaled ozone in mice:
Cachexia and down-regulation of liver xenobiotic metabolizing genes. *Toxicol Appl Pharmacol*
2005;208:117–126.
- 45 33. Bocci V. Interleukins. Clinical pharmacokinetics and practical implications. *Clin Pharmacokinet*
1991;21:274–284.
- 47 34. Bocci V. Physicochemical and biologic properties of interferons and their potential uses in drug
delivery systems. *Crit Rev Ther Drug Carrier Syst* 1992;9:91–133.
- 49 35. Alary J, Geuraud F, Cravedi JP. Fate of 4-hydroxynonenal in vivo: Disposition and metabolic
pathways. *Mol Aspects Med* 2003;24:177–187.

- 1 36. Siems W, Grune T. Intracellular metabolism of 4-hydroxynonenal. *Mol Aspects Med* 2003;24:167–175.
- 3 37. Awasthi YC, Ansari GA, Awasthi S. Regulation of 4-hydroxynonenal mediated signaling by glutathione *S*-transferase. *Methods Enzymol* 2005;401:379–407.
- 5 38. Sweet F, Kao MS, Lee SC, Hagar WL, Sweet WE. Ozone selectively inhibits growth of human cancer cells. *Science* 1980;209:931–933.
- 7 39. Tarkington BK, Duvall TR, Last JA. Ozone exposure of cultured cells and tissues. *Methods Enzymol* 1994;234:257–265.
- 9 40. Larini A, Bianchi L, Bocci V. The ozone tolerance: (I) Enhancement of antioxidant enzymes is ozone dose-dependent in Jurkat cells. *Free Radic Res* 2003;37:1163–1168.
- 11 41. Leist M, Raab B, Maurer S, Brigelius-Flohé R. Conventional cell culture media do not adequately supply cells with antioxidants and thus facilitate peroxide-induced genotoxicity. *Free Radic Biol Med* 1996;21:297–306.
- 13 42. Halliwell B. Antioxidants in human health and disease. *Annu Rev Nutr* 1996;16:33–50.
- 15 43. Halliwell B. Antioxidant defence mechanisms: From the beginning to the end (of the beginning). *Free Radic Res* 1999;31:261–272.
- 17 44. Halliwell B. Oxidative stress in cell culture: An under-appreciated problem? *FEBS Lett* 2003;540:3–6.
- 19 45. Larini A, Bianchi L, Bocci V. Effect of 4-hydroxynonenal on antioxidant capacity and apoptosis induction in Jurkat T cells. *Free Radic Res* 2004;38:509–516.
- 21 46. Larini A, Bocci V. Albumin is the most effective antioxidant during human plasma and blood ozonization. *Rivista Italiana di Ossigeno–Ozonoterapia* 2004;3:15–24.
- 23 47. Bocci V, Valacchi G, Corradeschi F, Aldinucci C, Silvestri S, Paccagnini E, Gerli R. Studies on the biological effects of ozone: 7. Generation of reactive oxygen species (ROS) after exposure of human blood to ozone. *J Biol Regul Homeost Agents* 1998;12:67–75.
- 25 48. Bocci V. Does ozone therapy normalize the cellular redox balance? *Med Hypotheses* 1996;46:150–154.
- 27 49. Bocci V. Scientific and medical aspects of ozone therapy. State of the art. *Arch Med Res* 2006;37:425–435.
- 29 50. Stoker G. The surgical uses of ozone. *Lancet* 1916;188:712.
- 31 51. Stoker G. The surgical uses of ozone. *Lancet* 1917;189:797.
- 33 52. Fish E. Apparatus for the production and use of ozone in therapeutics. United States Patent 2,054,367. September 15, 1936.
- 35 53. Kühnel K, Seifert V. Erwin Payr and his contributions to neurosurgery. *Zentralbl Neurochir* 1998;59:27–35.
- 37 54. Bocci V. Oxygen–ozone therapy. A critical evaluation. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2002. 440p.
- 39 55. Timbrell J. The poison paradox; chemicals as friends and foes. Oxford: Oxford University Press; 2005. 352p.
- 41 56. Hunter P. A toxic brew we cannot live without. Micronutrients give insight into the interplay between geochemistry and evolutionary biology. *EMBO Rep* 2008;9:15–18.
- 43 57. Cataldo F, Gentilini L. Chemical kinetics measurements on the reaction between blood and ozone. *Int J Biol Macromol* 2005;36:61–65.
- 45 58. Bocci V, Travagli V. How an ill-conceived methodological approach can condemn the medical use of ozone therapy. *Int J Biol Macromol* 2005;37:287–288.
- 47 59. Van der Vliet A, O’Neil CA, Eiserich JP, Cross CE. Oxidative damage to extracellular fluids by ozone and possible protective effects of thiols. *Arch Biochem Biophys* 1995;321:43–50.
- 49 60. Bocci V. The question of balance: The interaction between blood and ozone. In: Valacchi G, Davis P, editors. *Oxidants in biology*. The Netherlands: Springer; 2008. pp 155–165.

- 1 61. Cross CE, Reznick AZ, Packer L, Davis PA, Suzuki YJ, Halliwell B. Oxidative damage to human
plasma proteins by ozone. *Free Radic Res Commun* 1992;15:347–352.
- 3 62. Mulholland CW, Strain JJ. Total radical-trapping antioxidant potential (TRAP) of plasma:
Effects of supplementation. *Int J Vitam Nutr Res* 1993;63:27–30.
- 5 63. Bocci V, Aldinucci C. Biochemical modifications induced in human blood by oxygenation-
ozonation. *J Biochem Mol Toxicol* 2006;20:133–138.
- 7 64. Bocci V, Luzzi E, Corradeschi F, Paulesu L, Di Stefano A. Studies on the biological effects of
ozone: 3. An attempt to define conditions for optimal induction of cytokines. *Lymphokine*
9 *Cytokine Res* 1993;12:121–126.
- 11 65. Shinriki N, Suzuki T, Takama K, Fukunaga K, Ohgiya S, Kubota K, Miura T. Susceptibilities of
plasma antioxidants and erythrocyte constituents to low levels of ozone. *Haematologia*
1998;29:229–239.
- 13 66. Mendiratta S, Qu ZC, May JM. Erythrocyte ascorbate recycling: Antioxidant effects in blood.
Free Radic Biol Med 1998;24:789–797.
- 15 67. Mendiratta S, Qu ZC, May JM. Enzyme-dependent ascorbate recycling in human erythrocytes:
Role of thioredoxin reductase. *Free Radic Biol Med* 1998;25:221–228.
- 17 68. Uppu RM, Cueto R, Squadrito GL, Pryor WA. What does ozone react with at the air/lung
interface? Model studies using human red blood cell membranes. *Arch Biochem Biophys*
1995;319:257–266.
- 19 69. Pryor WA, Squadrito GL, Friedman M. The cascade mechanism to explain ozone toxicity: The
role of lipid ozonation products. *Free Radical Biol Med* 1995;19:935–941.
- 21 70. Halliwell B, Clement MV, Long LH. Hydrogen peroxide in the human body. *FEBS Lett*
2000;486:10–13.
- 23 71. Halliwell B, Clement MV, Ramalingam J, Long LH. Hydrogen peroxide: Ubiquitous in cell
culture and in vivo? *IUBMB Life* 2000;50:251–257.
- 25 72. Antunes F, Cadenas E. Estimation of H₂O₂ gradients across biomembranes. *FEBS Lett*
2000;475:121–126.
- 27 73. Bocci V, Aldinucci C, Bianchi L. The use of hydrogen peroxide as medical drug. *Rivista Italiana di*
Ossigeno-Ozonoterapia 2005;4:30–39.
- 29 74. Stone JR, Yang S. Hydrogen peroxide: A signaling messenger. *Antioxid Redox Signal* 2006;8:
243–270.
- 31 75. Forman HJ. Hydrogen peroxide: The good, the bad and the ugly. In: Valacchi G, Davis P, editors.
Oxidants in biology. The Netherlands: Springer; 2008. pp 1–17.
- 33 76. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. *Annu Rev*
Immunol 1994;12:141–179.
- 35 77. Los M, Droge W, Stricker K, Baeuerle PA, Schulze-Osthoff K. Hydrogen peroxide as a potent
activator of T lymphocyte functions. *Eur J Immunol* 1995;25:159–165.
- 37 78. Stone JR, Collins T. The role of hydrogen peroxide in endothelial proliferative responses.
Endothelium 2002;9:231–238.
- 39 79. Grisham MB. Reactive oxygen species in immune responses. *Free Radic Biol Med* 2004;36:
1479–1480.
- 41 80. Ardanaz N, Pagano PJ. Hydrogen peroxide as a paracrine vascular mediator: Regulation and
signaling leading to dysfunction. *Exp Biol Med* 2006;231:237–251.
- 43 81. Allen RC, Loose LD. Phagocytic activation of a luminol-dependent chemiluminescence in rabbit
alveolar and peritoneal macrophages. *Biochem Biophys Res Commun* 1976;69:245–252.
- 45 82. Urschel HC. Cardiovascular effects of hydrogen peroxide: Current status. *Dis Chest* 1967;51:
180–192.
- 47 83. Lacy F, O'Connor DT, Schmid-Schonbein GW. Plasma hydrogen peroxide production in
hypertensives and normotensive subjects at genetic risk of hypertension. *J Hypertens* 1998;
49 16:291–303.

- 1 84. Matoba T, Shimokawa H, Kubota H, Morikawa K, Fujiki T, Kunihiro I, Mukai Y, Hirakawa Y,
3 Takeshita A. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human
mesenteric arteries. *Biochem Biophys Res Commun* 2002;290:909–913.
- 5 85. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. *Methods Enzymol*
1994;234:279–293.
- 7 86. Bocci V, Luzzi E, Corradeschi F, Paulesu L, Rossi R, Cardaioli E, Di Simplicio P. Studies on the
biological effects of ozone: 4. Cytokine production and glutathione levels in human erythrocytes.
J Biol Regul Homeost Agents 1993;7:133–138.
- 9 87. Packer L, Roy S, Sen CK. Alpha-lipoic acid: A metabolic antioxidant and potential redox
modulator of transcription. *Adv Pharmacol* 1997;38:79–101.
- 11 88. Petersen DR, Doorn JA. Reactions of 4-hydroxynonenal with proteins and cellular targets. *Free
Radic Biol Med* 2004;37:937–945.
- 13 89. Poli G, Schaur RJ, Siems WG, Leonarduzzi G. 4-Hydroxynonenal: A membrane lipid oxidation
product of medicinal interest. *Med Res Rev* 2008;28:569–631.
- 15 90. Toyokuni S, Yamada S, Kashima M, Ihara Y, Yamada Y, Tanaka T, Hiai H, Seino Y, Uchida K.
Serum 4-hydroxy-2-nonenal-modified albumin is elevated in patients with type 2 diabetes mellitus.
Antioxid Redox Signal 2000;2:681–685.
- 17 91. Aldini G, Gamberoni L, Orioli M, Beretta G, Regazzoni L, Maffei Facino R, Carini M. Mass
spectrometric characterization of covalent modification of human serum albumin by 4-hydroxy-
19 trans-2-nonenal. *J Mass Spectrom* 2006;41:1149–1161.
- 21 92. Aldini G, Vistoli G, Regazzoni L, Gamberoni L, Facino RM, Yamaguchi S, Uchida K, Carini M.
Albumin is the main nucleophilic target of human plasma: A protective role against pro-
23 atherogenic electrophilic reactive carbonyl species? *Chem Res Toxicol* 2008;21:824–835.
- 25 93. Selley ML, Bartlett MR, McGuinness JA, Hapel AJ, Ardlie NG, Lacey MJ. Determination of the
lipid peroxidation product trans-4-hydroxy-2-nonenal in biological samples by high-performance
27 liquid chromatography and combined capillary column gas chromatography-negative-ion
chemical ionisation mass spectrometry. *J Chromatogr* 1989;488:329–340.
- 29 94. Gil L, Siems W, Mazurek B, Gross J, Schroeder P, Voss P, Grune T. Age-associated analysis
of oxidative stress parameters in human plasma and erythrocytes. *Free Radic Res*
2006;40:495–505.
- 31 95. Esterbauer H, Zollner H, Lang J. Metabolism of the lipid peroxidation product 4-hydroxynonenal
by isolated hepatocytes and by liver cytosolic fractions. *Biochem J* 1985;228:363–373.
- 33 96. Siems W, Zollner H, Esterbauer H. Metabolic pathways of lipid peroxidation product
4-hydroxynonenal in hepatocytes. Quantitative assessment of an antioxidative defense system.
35 *Free Radic Biol Med* 1990;9:110.
- 37 97. Ramana KV, Bhatnagar A, Srivastava S, Yadav UC, Awasthi S, Awasthi YC, Srivastava SK.
Mitogenic responses of vascular smooth muscle cells to lipid peroxidation-derived
39 aldehyde 4-hydroxy-trans-2-nonenal (HNE): Role of aldose reductase-catalyzed reduction
of the HNE-glutathione conjugates in regulating cell growth. *J Biol Chem* 2006;281:
17652–17660.
- 41 98. Alary J, Bravais F, Cravedu JP, Debrauwer L, Rao D, Bories G. Mercapturic acid conjugates as
urinary end metabolites of the lipid peroxidation product 4-hydroxynonenal in the rat. *Chem Res
Toxicol* 1995;8:34–39.
- 43 99. Forman HJ, Dickinson DA, Iles KE. HNE-signaling pathways leading to its elimination. *Mol
Aspects Med* 2003;24:189–194.
- 45 100. Forman HJ, Dickinson DA. Introduction to serial reviews on 4-hydroxy-2-nonenal as a signaling
molecule. *Free Radic Biol Med* 2004;37:594–596.
- 47 101. Schaur RJ, Zollner H, Esterbauer H. Biological effects of aldehydes with particular attention to
49 hydroxynonenal and malondialdehyde. In: Vigo-Pelfrey C, editor. *Membrane lipid peroxidation*.
Boca Raton, FL: CRC Press; 1991. pp 141–163.

- 1 102. Leonarduzzi G, Parola M, Muzio G, Garramone A, Maggiora M, Robino G, Poli G, Dianzani
MU, Canuto RA. Hepatocellular metabolism of 4-hydroxy-2,3-nonenal is impaired in conditions
3 of chronic cholestasis. *Biochem Biophys Res Comm* 1995;214:669–675.
103. Petras T, Siems W, Grune T. 4-Hydroxynonenal is degraded to mercapturic acid conjugate in rat
5 kidney. *Free Radic Biol Med* 1995;19:685–688.
104. Jardines D, Correa T, Ledea O, Zamora Z, Rosado A, Molerio J. Gas chromatography-mass
7 spectrometry profile of urinary organic acids of Wistar rats orally treated with ozonized
unsaturated triglycerides and ozonized sunflower oil. *J Chromatogr B Analyt Technol Biomed
9 Life Sci* 2003;783:517–525.
105. Dianzani MU. 4-Hydroxynonenal from pathology to physiology. *Mol Aspects Med* 2003;24:
11 263–272.
106. Leonarduzzi G, Robbesyn F, Poli G. Signaling kinases modulated by 4-hydroxynonenal. *Free
13 Radic Biol Med* 2004;37:1694–1702.
107. Yang YS, Sharma R, Sharma A, Awasthi S, Awasthi YC. Lipid peroxidation and cell cycle
15 signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling. *Acta Biochim Pol*
2003;50:319–336.
108. Dwivedi S, Sharma A, Patrick B, Sharma R, Awasthi YC. Role of 4-hydroxynonenal and its
17 metabolites in signaling. *Redox Rep* 2007;12:4–10.
109. Kutuk O, Basaga H. Apoptosis signalling by 4-hydroxynonenal: A role for JNK-c-Jun/AP-1
19 pathway. *Redox Rep*. 2007;12:30–34.
110. Comporti M, Signorini C, Arezzini B, Vecchio D, Monaco B, Gardi C. F2-isoprostanes are not
21 just markers of oxidative stress. *Free Radic Biol Med* 2008;44:247–256.
111. Travagli V, Zanardi I, Bocci V. A realistic evaluation of the action of ozone on whole human
23 blood. *Int J Biol Macromol* 2006;39:317–320.
112. Travagli V, Zanardi I, Silvietti A, Bocci V. A physicochemical investigation on the effects of ozone
25 on blood. *Int J Biol Macromol* 2007;41:504–511.
113. Goldstein BD, Balchum OJ. Effect of ozone on lipid peroxidation in the red blood cell. *Exp Biol
27 Med* 1967;126:356–358.
114. Freeman BA, Miller BE, Mudd JB. Reaction of ozone with human erythrocytes. In: Lee SD,
29 Mudd JB, editors. *Assessing toxic effects of environmental pollutants*. Ann Arbor, MI:
Ann Arbor Science Publisher; 1979. pp 151–171.
115. Van der Zee J, van Beek E, Dubbelman TMAR, van Stevenick J. Toxic effects of ozone on murine
31 L929 fibroblasts. Damage to DNA. *Biochem J* 1987;247:69–72.
116. Fukunaga K, Nakazono N, Suzuki T, Takama K. Mechanism of oxidative damage to fish red
33 blood cells by ozone. *IUBMB Life* 1999;48:631–634.
117. Górnicki A, Gutsze A. In vitro effects of ozone on human erythrocyte membranes: An EPR study.
35 *Acta Biochim Pol* 2000;47:963–971.
118. Du Plessis LH, Van der Westhuizen FH, Kotze HF. The effect of blood ozonation on
37 mitochondrial function and apoptosis of peripheral blood mononuclear cells in the presence and
absence of antioxidants. *Afr J Biotechnol* 2007;6:1763–1769.
119. Du Plessis LH, Van der Westhuizen FH, Kotze HF. The protective effect of plasma antioxidants
41 during ozone autohemotherapy. *Afr J Biotechnol* 2008;7:2472–2477.
120. Galleano M, Puntaruolo S. Role of antioxidants on the erythrocytes resistance to lipid
43 peroxidation after acute iron overload in rats. *Biochim Biophys Acta* 1995;1271:321–326.
121. Caglayan S, Bayer R. Effects of oxydative stress on erythrocyte deformability and fragility. *Proc
45 SPIE* 2100 1994;182:183–189.
122. Hernández F, Menéndez S, Wong R. Decrease of blood cholesterol and stimulation of
47 antioxidative response in cardiopathy patients treated with endovenous ozone therapy. *Free
49 Radic Biol Med* 1995;19:115–119.

- 1 123. Hernández Rosales FA, Calunga Fernández JL, Turrent Figueras J, Menéndez Cepero S,
 3 Montenegro Perdomo A. Ozone therapy effects on biomarkers and lung function in asthma. *Arch*
 5 *Med Res* 2005;36:549–554.
124. Bocci V, Venturi G, Catucci M, Valensin PE, Zazzi M. Lack of efficacy of ozone therapy in HIV
 7 infection. *Clin Microbiol Infect* 1998;4:667–669.
125. Burgassi S, Zanardi I, Travagli V, Montomoli M, Bocci V. How much ozone bactericidal activity
 9 is compromised by plasma components? *J Appl Microbiol* 2008, accepted.
126. Margalit M, Attias E, Attias D, Elstein D, Zimran A, Matzner Y. Effect of ozone on neutrophil
 11 duction in vitro. *Clin Lab Haematol* 2001;23:243–247.
127. Larini A, Bocci V. Effects of ozone on isolated peripheral blood mononuclear cells. *Toxicol*
 13 *In Vitro* 2005;19:55–61.
128. Bocci V, Paulesu L. Studies on the biological effects of ozone 1. Induction of interferon on human
 15 gamma leucocytes. *Haematologica* 1990;75:510–515.
129. Bocci V. Roles of interferon produced in physiological conditions. A speculative review.
 17 *Immunology* 1988;64:1–9.
130. Bocci V, Valacchi G, Corradeschi F, Fanetti G. Studies on the biological effects of ozone: 8. Effects
 19 on the total antioxidant status and on interleukin-8 production. *Mediators Inflamm* 1998;7:313–317.
131. Bocci V, Valacchi G, Rossi R, Giustarini D, Paccagnini E, Pucci AM, Di Simplicio P. Studies on
 21 the biological effects of ozone: 9. Effects of ozone on human platelets. *Platelets* 1999;10:110–116.
132. Valacchi G, Bocci V. Studies on the biological effects of ozone: 10. Release of factors from
 23 ozonated human platelets. *Mediators Inflamm* 1999;8:205–209.
133. Valacchi G, Bocci V. Studies on the biological effects of ozone: 11. Release of factors from human
 25 endothelial cells. *Mediators Inflamm* 2000;9:271–276.
134. Stamler JS. *S*-nitrosothiols in the blood: Roles, amounts, and methods of analysis. *Circ Res*
 27 2004;94:414–417.
135. Gladwin MT, Schechter AN. NO contest: Nitrite versus *S*-nitroso-hemoglobin. *Circ Res*
 29 2004;94:851–855.
136. Foresti R, Bains S, Sulc F, Farmer PJ, Green CJ, Motterlini R. The interaction of nitric oxide with
 31 distinct hemoglobins differentially amplifies endothelial heme uptake and heme oxygenase-1
 33 expression. *J Pharmacol Exp Ther* 2006;317:1125–1133.
137. Dianzani MU. 4-Hydroxynonenal and cell signalling. *Free Radic Res* 1998;28:553–560.
138. Bocci V. Ozone. A new medical drug. Dordrecht, The Netherlands: Springer; 2005; 295p.
139. Bocci V. Rectal insufflation of oxygen–ozone. Ozone. A new medical drug. Dordrecht, The
 35 Netherlands: Springer; 2005. pp 49–56.
140. Bocci V. Quasi-total body exposure to oxygen–ozone. Ozone. A new medical drug. Dordrecht,
 37 The Netherlands: Springer; 2005. pp 56–65.
141. Bocci V. Extracorporeal blood circulation against oxygen–ozone. Ozone. A new medical drug.
 39 Dordrecht, The Netherlands: Springer; 2005. pp 66–73.
142. Bocci V. Minor ozone autohemotherapy. Ozone. A new medical drug. Dordrecht, The
 41 Netherlands: Springer; 2005. pp 42–44.
143. Bocci V. Infection diseases (bacterial, viral, fungal, parasitic). Ozone. A new medical drug.
 43 Dordrecht, The Netherlands: Springer; 2005. pp 100–122.
144. Bocci V. Retinal degenerative disorders. Ozone. A new medical drug. Dordrecht, The
 45 Netherlands: Springer; 2005. pp 132–144.
145. Bocci V. The paradoxical effect of ozone in orthopaedic diseases. The problem of back-ache.
 47 Ozone. A new medical drug. Dordrecht, The Netherlands: Springer; 2005. pp 198–208.
146. Bocci V. The dilemma between hyperbaric oxygen therapy (HOT) and ozonotherapy. Ozone.
 49 A new medical drug. Dordrecht, The Netherlands: Springer; 2005. pp 227–230.
147. Kangasjärvi J, Talvinen J, Utriainen M, Karjalainen R. Plant defence system induced by ozone.
Plant Cell Environ 1994;17:783–794.

- 1 148. Sharma YK, León J, Raskin I, Davis KR. Ozone-induced responses in *Arabidopsis thaliana*: The
 3 role of salicylic acid in the accumulation of defense-related transcripts and induced resistance.
 Proc Natl Acad Sci USA 1996;93:5099–5104.
149. Desikan R, Neill SJ, Hencock JT. Hydrogen peroxide-induced gene expression in *Arabidopsis*
 5 *thaliana*. Free Radic Biol Med 2000;28:773–778.
150. Ranieri A, Petacco F, Castagna A, Soldatini GF. Redox state and peroxidase system in sunflower
 7 plants exposed to ozone. Plant Sci 2001;159:159–167.
151. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury
 9 in ischemic myocardium. Circulation 1986;74:1124–1136.
152. Kume M, Yamamoto Y, Saad S, Gomi T, Kimoto S, Shimabukuro T, Yagi T, Nakagami M,
 11 Takada Y, Morimoto T, Yamaoka Y. Ischemic preconditioning of the liver in rats: Implications
 of heat shock protein induction to increase tolerance of ischemia-reperfusion injury. J Lab Clin
 13 Med 1996;28:251–258.
153. León OS, Menéndez S, Merino N, Castillo R, Sam S, Pérez L, Cruz E, Bocci V. Ozone oxidative
 15 preconditioning: A protection against cellular damage by free radicals. Mediators Inflamm
 1998;7:289–294.
154. Sun JS, Lu FJ, Huang WC, Hou SM, Tsuang YH, Hang YS. Antioxidant status following acute
 17 ischemic limb injury: A rabbit model. Free Radic Res 1999;31:9–21.
155. Barber E, Menéndez S, León OS, Barber MO, Merino N, Calunga JL, Cruz E, Bocci V.
 19 Prevention of renal injury after induction of ozone tolerance in rats submitted to warm ischaemia.
 Mediators Inflamm 1999;8:37–41.
156. Yamamoto H, Yamamoto Y, Yamagami K, Kume M, Kimoto S, Toyokuni S, Uchida K,
 23 Fukumoto M, Yamaoka Y. Heat-shock preconditioning reduces oxidative protein denaturation
 and ameliorates liver injury by carbon tetrachloride in rats. Res Exp Med (Berl) 2000;199:309–318.
157. Peralta C, Xaus C, Bartrons R, Leon OS, Gelpi E, Roselló-Catafau J. Effect of ozone treatment
 25 on reactive oxygen species and adenosine production during hepatic ischemia-reperfusion. Free
 Radic Res 2000;33:595–605.
158. Goldman M. Cancer risk of low-level exposure. Science 1996;271:1821–1822.
159. Wolff S. Aspects of the adaptive response to very low doses of radiation and other agents. Mutat
 29 Res 1996;358:135–142.
160. Calabrese EJ. Paradigm lost, paradigm found: The re-emergence of hormesis as a fundamental
 31 dose response model in the toxicological sciences. Environ Pollut 2005;138:379–411.
161. Calabrese EJ. Hormesis and medicine. Br J Clin Pharmacol 2008, in press.
162. Stark M. Hormesis, adaptation, and the sandpile model. Crit Rev Toxicol 2008;38:641–644.
163. Olivieri G, Bodycote J, Wolff S. Adaptive response of human lymphocytes to low concentrations
 35 of radioactive thymidine. Science. 1984;223:594–597.
164. Iles KE, Liu RM. Mechanisms of glutamate cysteine ligase (GCL) induction by
 37 4-hydroxynonenal. Free Radic Biol Med 2005;38:547–556.
165. Maines MD. The heme oxygenase system: A regulator of second messenger gases. Annu Rev
 39 Pharmacol Toxicol 1997;37:517–554.
166. Bach FH. Heme oxygenase-1 as a protective gene. Wien Klin Wochenschr 2002;114:1–3.
167. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: A major physiologic
 43 cytoprotectant. Proc Natl Acad Sci USA 2002;99:16093–16098.
168. Zuckerbraun BS, Billiar TR. Heme oxygenase-1: A cellular Hercules. Hepatology 2003;37:742–744.
169. Iles KE, Dickinson DA, Wigley AF, Welty NE, Blank V, Forman HJ. HNE increases HO-1
 45 through activation of the ERK pathway in pulmonary epithelial cells. Free Radic Biol Med
 2005;39:355–364.
170. Bocci V, Aldinucci C, Mosci F, Carraro F, Valacchi G. Ozonation of human blood induces a
 47 remarkable upregulation of heme oxygenase-1 and heat stress protein-70. Mediators Inflamm
 2007;2007:26785.

- 1 171. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. *Pharmacol Rev* 2008;60:79–127.
- 3 172. Balla G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F, Eaton JW, Vercellotti GM. Ferritin: A cytoprotective antioxidant strategem of endothelium. *J Biol Chem* 1992;267:18148–18153.
- 5 173. Su WY, Gordon T. In vivo exposure to ozone produces an increase in a 72-kDa heat shock protein in guinea pigs. *J Appl Physiol* 1997;83:707–711.
- 7 174. Polidori MC, Mecocci P, Levine M, Frei B. Short-term and long-term vitamin C supplementation in humans dose-dependently increases the resistance of plasma to ex vivo lipid peroxidation. *Arch Biochem Biophys* 2004;423:109–115.
- 9 175. Victor VM, McCreath KJ, Rocha M. Recent progress in pharmacological research of antioxidants in pathological conditions: Cardiovascular health. *Recent Patents Anti Infect Drug Discov* 2006;1:17–31.
- 11 176. Roberts 2nd LJ, Oates JA, Linton MF, Fazio S, Meador BP, Gross MD, Shyr Y, Morrow JD. The relationship between dose of vitamin E and suppression of oxidative stress in humans. *Free Radic Biol Med* 2007;43:1388–1393.
- 13 177. Bocci V, Borrelli E, Corradeschi F, Valacchi G. Systemic effects after colorectal insufflation of oxygen/ozone in rabbit. *Int J Med Biol Environ* 2000;28:109–113.
- 15 178. Eliakim R, Karmeli F, Rachmilewitz D, Cohen P, Zimran A. Ozone enema: A model of microscopic colitis in rats. *Dig Dis Sci* 2001;46:2515–2520.
- 17 179. Bocci V, Borrelli E, Valacchi G, Luzzi E. Quasi-total-body exposure to an oxygen–ozone mixture in a sauna cabin. *Eur J Appl Physiol Occup Physiol* 1999;80:549–554.
- 19 180. Bocci V, Di Paolo N. Oxygenation–ozonation of blood during extracorporeal circulation (EBOO). Part III: A new medical approach. *Ozone Sci Eng* 2004;26:195–205.
- 21 181. Bocci V, Zanardi I, Travagli V, Di Paolo N. Oxygenation–ozonation of blood during extracorporeal circulation: In vitro efficiency of a new gas exchange device. *Artif Organs* 2007;31:743–748.
- 23 182. Jacobs MT. Untersuchung uber zwishenfälle und typische komplikationen in der ozon-sauerstofftherapie. *OzoNachrichten* 1982;5:1–5.
- 25 183. Rokitanski O, Rokitanski A, Steriner J, Trubel W, Viebahn R, Washüttl J. Die ozontherapie bei peripheren, arteriellen durchblutungs-störungen; klinik, biochemische und blutgasanalytische untersuchungen. In: Wasser IOA, editor. Berlin: Ozon-Weltkongress; 1981. pp 53–75.
- 27 184. Rokitanski O. Klinik und biochemie der ozontherapie. *Hospitalis* 1982;52:643–647.
- 29 185. Matassi R, D'Angelo F, Bisetti P, Colombo R, Vaghi M. Terapia con ozono per via parenterale nelle arteropatie obliteranti periferiche: Meccanismo biochimico e risultati clinici. *Il Giornale di Chirurgia* 1987;VIII:109–111.
- 31 186. Di Paolo N, Bocci V, Salvo DP, Palasciano G, Biagioli M, Meini S, Galli F, Ciari I, Maccari F, Cappelletti F, Di Paolo M, Gaggiotti E. Extracorporeal blood oxygenation and ozonation (EBOO): A controlled trial in patients with peripheral artery disease. *Int J Artif Organs* 2005;28:1039–1050.
- 33 187. De Monte A, van der Zee H, Bocci V. Major ozonated autohemotherapy in chronic limb ischemia with ulcerations. *J Altern Complement Med* 2005;11:363–367.
- 35 188. Giunta R, Coppola A, Luongo C, Sammartino A, Guastafierro S, Grassia A, Giunta L, Mascolo L, Tirelli A, Coppola L. Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease. *Ann Hematol* 2001;80:745–748.
- 37 189. Tylicki L, Nieweglowski T, Biedunkiewicz B, Burakowski S, Rutkowski B. Beneficial clinical effects of ozonated autohemotherapy in chronically dialysed patients with atherosclerotic ischemia of the lower limbs—pilot study. *Int J Artif Organs* 2001;24:79–82.
- 39 190. Tylicki L, Nieweglowski T, Biedunkiewicz B, Chamienia A, Debska-Slizien A, Aleksandrowicz E, Lysiak-Szydłowska W, Rutkowski B. The influence of ozonated autohemotherapy on oxidative

- 1 stress in hemodialyzed patients with atherosclerotic ischemia of lower limbs. *Int J Artif Organs* 2003;26:297–303.
- 3 191. Clavo B, Pérez JL, López L, Suárez G, Lloret M, Rodríguez V, Macías D, Santana M, Morera J, Fiuza D, Robaina F, Günderoth M. Effect of ozone therapy on muscle oxygenation. *J Altern*
5 *Complement Med* 2003;9:251–256.
192. Clavo B, Catalá L, Pérez JL, Rodríguez V, Robaina F. Ozone therapy on cerebral blood flow: A preliminary report. *Evid Based Complement Altern Med* 2004;1:315–319.
- 7 193. Tylicki L, Biedunkiewicz B, Nieweglowski T, Chamienia A, Slizien AD, Luty J, Lysiak-Szydłowska W, Rutkowski B. Ozonated autohemotherapy in patients on maintenance hemodialysis: Influence on lipid profile and endothelium. *Artif Organs* 2004;28:234–247.
- 9 194. Biedunkiewicz B, Tylicki L, Nieweglowski T, Burakowski S, Rutkowski B. Clinical efficacy of ozonated autohemotherapy in hemodialyzed patients with intermittent claudication: An oxygen-controlled study. *Int J Artif Organs* 2004;27:29–34.
- 11 195. Torre-Amione G, Anker SD, Bourge RC, Colucci WS, Greenberg BH, Hildebrandt P, Keren A, Motro M, Moyé LA, Otterstad JE, Pratt CM, Ponikowski P, Rouleau JL, Sestier F, Winkelmann BR, Young JB. Advanced chronic heart failure clinical assessment of immune modulation therapy investigators. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): A placebo-controlled randomised trial. *Lancet* 2008;371:228–236.
- 13 196. Cooke ED, Pockley AG, Tucker AT, Kirby JDT, Bolton AE. Treatment of severe Raynaud's syndrome by injection of autologous blood pretreated by heating, ozonation and exposure to ultraviolet light (H-O-U) therapy. *Int Angiol* 1997;16:250–254.
- 15 197. Sliwa K, Ansari AA. Immunosuppression as therapy for congestive heart failure. *Lancet* 2008;371:184–186.
- 17 198. Fildes JE, Shaw SM, Yonan N, Williams SG. Non-specific immunomodulation in chronic heart failure. *Lancet* 2008;37:2083.
- 19 199. Bocci V. Non-specific immunomodulation in chronic heart failure. *Lancet* 2008;37:2083. Q6
- 21 200. Bocci V. The failure of the ACCLAIM trial is due to an irrational technology. *Int J Cardiol* 2008, IJCA11249, in press.
- 23 201. Olin JW. A multicenter, randomized, double-blind, placebo-controlled study of immune modulation therapy in patients with symptomatic peripheral arterial disease: The SIMPADICO trial. American College of Cardiology 55th Annual Scientific Sessions, Atlanta, GA, March 11–14, 2006. Late-breaking clinical trials I.
- 25 202. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? *Br J Ophthalmol* 2003;87:312–317.
- 27 203. Krinsky NI, Landrum JT, Bone RA. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. *Annu Rev Nutr* 2003;23:171–201.
- 29 204. Coleman H, Chew E. Nutritional supplementation in age-related macular degeneration. *Curr Opin Ophthalmol* 2007;18:220–223.
- 31 205. Bocci V. Die senile makulopathie und verwandte erkrankungen. In: Viebahn-Hänsler R, Knoch HG, editors. *Ozon-Handbuch*. Vol. 5.1. Ecomed Verlag; 2001. pp 1–26. Q7
- 33 206. Berson EL, Remulla JF, Rosner B, Sandberg MA, Weigel-DiFranco C. Evaluation of patients with retinitis pigmentosa receiving electric stimulation, ozonated blood, and ocular surgery in Cuba. *Arch Ophthalmol* 1996;114:560–563.
- 35 207. Carpendale MT, Freeberg JK. Ozone inactivates HIV at noncytotoxic concentrations. *Antiviral Res* 1991;16:281–292.
- 37 208. Sechi LA, Lezcano I, Nunez N, Espim M, Duprè I, Pinna A, Molicotti P, Fadda G, Zanetti S. Antibacterial activity of ozonized sunflower oil (Oleozon). *J Appl Microbiol* 2001;90:279–284.
- 39 209. Church L. Ionozone therapy for skin lesions in elderly patients. *Physiotherapy* 1980;66:50–51.

- 1 210. Turčić J, Hancević J, Antoljak T, Zic R, Alfirević I. Effects of ozone on how well split-thickness
3 skin grafts according to Thiersch take in war wounds. Results of prospective study. *Langenbecks*
Arch Chir 1995;380:144–148.
- 5 211. Matsumoto A, Sakurai S, Shinriki N, Suzuki S, Miura T. Therapeutic effects of ozonized olive oil
7 in the treatment of intractable fistula and wound after surgical operation. Proceedings of the 15th
Ozone World Congress, Vol. 1, London, UK. London, UK: Speedprint MacMedia; 2001.
pp 77–84.
- 9 212. Valacchi G, Fortino V, Bocci V. The dual action of ozone on the skin. *Br J Dermatol*
2005;153:1096–1100.
- 11 213. He QC, Tavakkol A, Wietecha K, Begum-Gafur R, Ansari SA, Polefka T. Effects of
environmentally realistic levels of ozone on stratum corneum function. *Int J Cosmet Sci*
2006;28:349–357.
- 13 214. Zanardi I, Travagli V, Gabbrielli A, Chiasserini L, Bocci V. Physico-chemical characterization of
sesame oil derivatives. *Lipids* 2008;43:877–886.
- 15 215. Jordan L, Beaver K, Foy S. Ozone treatment for radiotherapy skin reactions: Is there an evidence
base for practice? *Eur J Oncol Nurs* 2002;6:220–227.
- 17 216. Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. *Lancet*
2005;366:1725–1735.
- 19 217. Martínez-Sánchez G, Al-Dalain SM, Menéndez S, Re L, Giuliani A, Candelario-Jalil E,
21 Alvarez H, Fernández-Montequín JI, León OS. Therapeutic efficacy of ozone in patients with
diabetic foot. *Eur J Pharmacol* 2005;523:151–161.
- 23 218. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists
and corticosteroids. *Eur Respir J* 2002;19:182–191.
- 25 219. Bocci V. May oxygen-ozonotherapy improve the prognosis of BPCO? *Giorn It Mal Tor*
2007;61:434–446.
- 27 220. Andreula CF, Simonetti L, De Santis F, Agati R, Ricci R, Leonardi M. Minimally
invasive oxygen–ozone therapy for lumbar disk herniation. *AJNR Am J Neuroradiol*
2003;996–1000.
- 29 221. Gallucci M, Limbucci N, Zugaro L, Barile A, Stavroulis E, Ricci A, Galzio R, Masciocchi C.
31 Sciatica: Treatment with intradiscal and intraforaminal injections of steroid and oxygen–ozone
versus steroid only. *Radiology* 2007;242:907–913.
- 33 222. Oder B, Loewe M, Reissegger M, Lang W, Ilias W, Thurnher SA. CT-guided ozone/steroid therapy
for the treatment of degenerative spinal disease-effect of age, gender, disc pathology and multi-
segmental changes. *Neuroradiology* 2008;50:777–785.
- 35 223. Muto M, Ambrosiano G, Guarnieri G, Capobianco E, Piccolo G, Annunziata G, Rotondo A.
37 Low back pain and sciatica: Treatment with intradiscal-intraforaminal O(2)–O(3) injection. Our
experience. *Radiol Med* 2008;113:695–706.
- 39 224. Wu ZQ, Wei LZ, Li J, Wanga Y, Ni DH, Yang P, Zhang Y. Percutaneous treatment of non-
contained lumbar disc herniation by injection of oxygen–ozone combined with collagenase. *Eur J*
Radiol 2008, in press. DOI: 10.1016/j.ejrad.2008.07.029.
- 41 225. Re L, Martínez-Sánchez G, Malcangi G, Mercanti A, Labate V. Ozone therapy: A clinical study
on the pain management. *Int J Ozone Therapy* 2008;7:37–44.
- 43 226. Bochkov VN, Leitinger N. Anti-inflammatory properties of lipid oxidation products. *J Mol Med*
2003;81:613–626.
- 45 227. Tamoto K, Yamazaki A, Nochi H, Miura T. Ozonides of olive oil and methyl oleate inhibit the
47 expression of cyclooxygenase 2 through the suppression of kB/NFkB pathway in lipopolysac-
charide-stimulated macrophage-like THP1 cells. Proceedings of the 17th World Ozone
Association Congress, Strasbourg, France, 2005. p 37.
- 49 228. Baysan A, Whiley RA, Lynch E. Antimicrobial effect of a novel ozone-generating device on micro-
organisms associated with primary root carious lesions in vitro. *Caries Res* 2000;34:498–501.

- 1 229. Azarpazhooh A, Limeback H. The application of ozone in dentistry: A systematic review of
literature. *J Dent* 2008;36:104–116.
- 3 230. Lynch E. The revolution in dentistry. Copenhagen: Quintessence Publisher; 2004; 300p.
231. Weaver LK, Hopkins RO, Chan KJ, Churchill S, Elliott CG, Clemmer TP, Orme Jr JF,
5 Thomas FO, Morris AH. Hyperbaric oxygen for acute carbon monoxide poisoning. *N Engl J Med*
2002;347:1057–1067.
- 7 232. Cianci P. Advances in the treatment of the diabetic foot: Is there a role for adjunctive hyperbaric
oxygen therapy? *Wound Repair Regen* 2004;12:2–10.
- 9 233. Gill AL, Bell CN. Hyperbaric oxygen: Its uses, mechanisms of action and outcomes. *QJM*
2004;97:385–395.
- 11 234. Ohsawa I, Ishikawa M, Takahashi K, Watanabe M, Nishimaki K, Yamagata K, Katsura K,
Katayama Y, Asoh S, Ohta S. Hydrogen acts as a therapeutic antioxidant by selectively reducing
13 cytotoxic oxygen radicals. *Nat Med* 2007;13:688–694.
235. Wood KC, Gladwin MT. The hydrogen highway to reperfusion therapy. *Nat Med* 2007;13:
15 673–674.
236. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, Meng Q, Mustafa AK, Mu W, Zhang S,
17 Snyder SH, Wang R. H₂S as a physiologic vasorelaxant: Hypertension in mice with deletion of
cystathionine gamma-lyase. *Science* 2008;322:587–590.

21 **Velio Bocci, M.D., Ph.D.**, in *Physiology*. He is an Emeritus Professor of Physiology at the
23 University of Siena, Italy. His main research fields are plasma proteins characterization and
labelling; metabolism and pharmacokinetics of interferons and cytokines; biological and medical
25 evaluation of oxygen–ozone therapy.

27 **Emma Borrelli, M.D., Ph.D.**, in *Cardiovascular Pathophysiology*. She is the Director of the
Laboratory of Cardiovascular pathology in the Department of Surgery and Bioengineering of
29 the University of Siena, Italy. Her research interest deals with cardiovascular pathology and the
application of ozone therapy.

31 **Valter Travagli** is an Associate Professor of Pharmaceutical Technology at the University of
33 Siena, Italy. His main research fields are the interactions of biological macromolecules with
degrading agents and the inner Quality concept for drugs, based on manufacturing processes.

35 **Iacopo Zanardi, Ph.D.**, in *Pharmaceutical Sciences*, Department of Pharmaceutical Chemistry
and Technology, University of Siena, Italy. His main research fields are the chemico-physical
37 evaluation of biological macromolecules and ozone therapy.

Author Queries Form







John Wiley

JOURNAL TITLE: MED

31/12/2008

ARTICLE NO: 08-047

Queries and / or remarks

Query No.	Details required	Author's response
Q1	Please confirm the running head.	
Q2	Please note that the citation Fisch is changed to Fish as per the reference list.	
Q3	Please provide closing quotes.	
Q4	Please update Ref. 125.	
Q5	Please update Ref. 161.	
Q6	Please update Ref. 200.	
Q7	Please provide place of publication for Ref. 205.	